| Mayo Clinic Health System-southeast Minnesota Region | |
|
404 W Fountain St Albert Lea MN 56007-2437 | |
| (507) 373-2384 | |
| Not Available |
| Full Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Speciality | Clinic/Center |
| Location | 404 W Fountain St, Albert Lea, Minnesota |
| Authorized Official Name and Position | Praveen Mekala (CFO) |
| Authorized Official Contact | 5075946449 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Mayo Clinic Health System-southeast Minnesota Region 1000 1st Dr Nw Austin MN 55912-2941 Ph: (507) 433-7351 | Mayo Clinic Health System-southeast Minnesota Region 404 W Fountain St Albert Lea MN 56007-2437 Ph: (507) 373-2384 |
| NPI Number | 1891701637 |
|---|---|
| Provider Enumeration Date | 08/01/2006 |
| Last Update Date | 03/23/2021 |
| Medicare PECOS PAC ID | 4385556703 |
|---|---|
| Medicare Enrollment ID | O20031104000408 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891701637 | NPI | - | NPPES |
| CD5413 | Other | MN | MCRR |
| 0512244 | Other | IA | IA MA |
| P375 | Other | MN | UCARE |
| 538K1AL | Other | MN | BCBS |
| CB3783 | Other | MCRR | |
| 136C4 | Other | MN | VA |
| CD7991 | Other | IA | MCRR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM1300X | Clinic/center - Multi-specialty | (* (Not Available)) | Primary |
| Provider Name | Hussam Jenad |
|---|---|
| Provider Type | Practitioner - Sleep Medicine |
| Provider Identifiers | NPI Number: 1174597322 PECOS PAC ID: 7214841972 Enrollment ID: I20031117000671 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael J Wolf |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1649255209 PECOS PAC ID: 4880598861 Enrollment ID: I20031121000220 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Philippe Bauer |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1871566166 PECOS PAC ID: 6901700707 Enrollment ID: I20031124000162 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Scott Joseph Benson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1063474518 PECOS PAC ID: 6608770433 Enrollment ID: I20031124000294 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anil N Kurup |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1023098332 PECOS PAC ID: 5092619502 Enrollment ID: I20031125000514 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Marcia W Johnson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1801876594 PECOS PAC ID: 8123922648 Enrollment ID: I20031125000557 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David J Bradley |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1215901707 PECOS PAC ID: 9537063078 Enrollment ID: I20031125000662 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Benjamin W Riley |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1053385419 PECOS PAC ID: 6709781008 Enrollment ID: I20031201000249 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Laurel A Littrell |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1932171808 PECOS PAC ID: 8224934435 Enrollment ID: I20031209000736 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shannon P Sheedy |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1497720189 PECOS PAC ID: 7113823337 Enrollment ID: I20031209000762 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nathan A Jacobson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1437137254 PECOS PAC ID: 9032015060 Enrollment ID: I20031210000804 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Henry J Schiller |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1124008057 PECOS PAC ID: 5991602286 Enrollment ID: I20031215000955 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Maurice L Enriquez-sarano |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1386621142 PECOS PAC ID: 4981501202 Enrollment ID: I20031216000096 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark J Enzler |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1285608273 PECOS PAC ID: 0648177972 Enrollment ID: I20031216000143 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sorin V Pislaru |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1447238803 PECOS PAC ID: 0547167884 Enrollment ID: I20031216000204 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Peter C Gay |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1891765228 PECOS PAC ID: 4486551660 Enrollment ID: I20031216000526 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Pankaj Shah |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1659476588 PECOS PAC ID: 4880591965 Enrollment ID: I20031217000151 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Patrick W Eiken |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1245205830 PECOS PAC ID: 2668379751 Enrollment ID: I20031217000184 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John V Politsch |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1346215720 PECOS PAC ID: 2264330950 Enrollment ID: I20031219000208 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Timothy J Kaufmann |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1417935131 PECOS PAC ID: 2062310766 Enrollment ID: I20031219000269 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Janel N Glantz |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1154307395 PECOS PAC ID: 7012816713 Enrollment ID: I20031231000683 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Timothy Kozelsky |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1790762128 PECOS PAC ID: 3173422821 Enrollment ID: I20040102000155 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Frank Cetta |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1306822549 PECOS PAC ID: 9931008570 Enrollment ID: I20040102000696 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher W Lindsay |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1104899822 PECOS PAC ID: 4284535113 Enrollment ID: I20040115000113 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David W Johnson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1730164070 PECOS PAC ID: 8820999626 Enrollment ID: I20040115000521 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rachel A Shimek |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1619026291 PECOS PAC ID: 1052214095 Enrollment ID: I20040128000817 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kathryn M Gruenwald |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1871561985 PECOS PAC ID: 0648173591 Enrollment ID: I20040129000180 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brent Ronald Bullis |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1831140441 PECOS PAC ID: 8123921715 Enrollment ID: I20040130000405 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Richard L Ellis |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1447255500 PECOS PAC ID: 6305749706 Enrollment ID: I20040202000338 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Roger Click |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1447237029 PECOS PAC ID: 9234032541 Enrollment ID: I20040202000444 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Naveen S Murthy |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1972538064 PECOS PAC ID: 5597668814 Enrollment ID: I20040202000540 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rohini Singh |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1518037324 PECOS PAC ID: 0648163071 Enrollment ID: I20040207000267 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Santhi Subramaniam |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1073588315 PECOS PAC ID: 6204720428 Enrollment ID: I20040210000244 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James L Homme |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1699749507 PECOS PAC ID: 0749174803 Enrollment ID: I20040210000582 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paul M Robelia |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1790762029 PECOS PAC ID: 5991694556 Enrollment ID: I20040311001308 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer C Granquist-meacham |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1932175338 PECOS PAC ID: 6204726359 Enrollment ID: I20040323000826 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John C Mccabe |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1205812864 PECOS PAC ID: 2365333986 Enrollment ID: I20040323001134 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Marcie L Billings |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1770569709 PECOS PAC ID: 6305738733 Enrollment ID: I20040329001154 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David A Woodrum |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1750353298 PECOS PAC ID: 0547255051 Enrollment ID: I20040415000485 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Craig Edward Daniels |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1629054069 PECOS PAC ID: 5395730410 Enrollment ID: I20040419000298 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jason Homme |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1497727374 PECOS PAC ID: 6709871700 Enrollment ID: I20040419000999 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Abraham Joseph |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1912981200 PECOS PAC ID: 3274520036 Enrollment ID: I20040426001347 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael S Helgeson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1427195106 PECOS PAC ID: 4183611429 Enrollment ID: I20040428000766 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert A Taylor |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1437139714 PECOS PAC ID: 5496743262 Enrollment ID: I20040503000483 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kristin M Kirsch |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1891770459 PECOS PAC ID: 7214925619 Enrollment ID: I20040504001219 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hamid Rehman |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1144290305 PECOS PAC ID: 0446249833 Enrollment ID: I20040511000271 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric E Williamson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1881666022 PECOS PAC ID: 9739179912 Enrollment ID: I20040518000796 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kathleen S Linnemann |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1689607673 PECOS PAC ID: 5395727457 Enrollment ID: I20040602001320 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shelly L Barker |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1447225628 PECOS PAC ID: 7517940075 Enrollment ID: I20040608000345 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric G Heegaard |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1407852197 PECOS PAC ID: 7113900135 Enrollment ID: I20040610001219 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katherine C Nickels |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1679545354 PECOS PAC ID: 3072598424 Enrollment ID: I20040621001299 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bettina Thompson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1497726582 PECOS PAC ID: 0749265049 Enrollment ID: I20040621001808 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Darlene R Bannon |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1033183702 PECOS PAC ID: 4082699111 Enrollment ID: I20040622001039 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James A Young |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1538126107 PECOS PAC ID: 1355327362 Enrollment ID: I20040629000447 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah J Crane |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1770553083 PECOS PAC ID: 8426034489 Enrollment ID: I20040629000821 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexander Lekah |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1891768750 PECOS PAC ID: 9133107113 Enrollment ID: I20040708000265 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Laurence J Eckel |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1740275296 PECOS PAC ID: 8527046101 Enrollment ID: I20040709001203 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Felix E Diehn |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1184604142 PECOS PAC ID: 3274512371 Enrollment ID: I20040714000112 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John Mullon |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1841277134 PECOS PAC ID: 0446239420 Enrollment ID: I20040714000783 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy L Conners |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1780657346 PECOS PAC ID: 3072592419 Enrollment ID: I20040719000457 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Cassie C Kennedy |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1407820566 PECOS PAC ID: 6608846464 Enrollment ID: I20040728001586 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ositadimma C Ugwu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1013989417 PECOS PAC ID: 0042281628 Enrollment ID: I20040805000792 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Iasmina Craici |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1033197934 PECOS PAC ID: 8224001938 Enrollment ID: I20040819000317 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jory M Burroughs |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1134169246 PECOS PAC ID: 9133192859 Enrollment ID: I20040819000409 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jana J Brand |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689633042 PECOS PAC ID: 7012983166 Enrollment ID: I20040909000426 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert E Nesse |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1477543999 PECOS PAC ID: 1951213453 Enrollment ID: I20040909000572 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas M Munger |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1942272380 PECOS PAC ID: 2668449711 Enrollment ID: I20040916000818 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric A Evans |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1932185295 PECOS PAC ID: 0749272466 Enrollment ID: I20040928000280 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Monique Freund |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1053390526 PECOS PAC ID: 2860461779 Enrollment ID: I20040928000702 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Heather M Osgood |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1003955766 PECOS PAC ID: 8224007802 Enrollment ID: I20040930000174 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rufus R Rodriguez |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1649257270 PECOS PAC ID: 8729990924 Enrollment ID: I20041001000720 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Guy S Reeder |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1467430678 PECOS PAC ID: 9032179577 Enrollment ID: I20041019000169 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Samuel Jayaprakash Asirvatham |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1932189750 PECOS PAC ID: 7517928989 Enrollment ID: I20041020000445 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kathryn M Schak |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1114997061 PECOS PAC ID: 0244291581 Enrollment ID: I20041020001148 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer L Tunnell |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1104809821 PECOS PAC ID: 8527029388 Enrollment ID: I20041025000635 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael S Meyers |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1962485854 PECOS PAC ID: 2163483884 Enrollment ID: I20041025001078 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kevin T Cragun |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1831175751 PECOS PAC ID: 7618939034 Enrollment ID: I20041028000648 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric J Youlden |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1083693220 PECOS PAC ID: 9739142548 Enrollment ID: I20041111000510 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paul Wennberg |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1407820921 PECOS PAC ID: 2264496876 Enrollment ID: I20041115000121 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael J Giorgi |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1699740654 PECOS PAC ID: 7719899988 Enrollment ID: I20041116000359 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy Koenigs |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871565564 PECOS PAC ID: 4880659036 Enrollment ID: I20041130000089 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nathan P Young |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1356314876 PECOS PAC ID: 8325003585 Enrollment ID: I20041130000187 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Steve M Kubas |
|---|---|
| Provider Type | Practitioner - Sleep Medicine |
| Provider Identifiers | NPI Number: 1093799827 PECOS PAC ID: 1658337381 Enrollment ID: I20041204000294 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kevin J Whitford |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1972581338 PECOS PAC ID: 5395731491 Enrollment ID: I20041209000222 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Monica M Loppnow |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1811980048 PECOS PAC ID: 4587612676 Enrollment ID: I20050105000645 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Grace Lin |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1285608547 PECOS PAC ID: 8426008061 Enrollment ID: I20050131001027 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kara M Schwartz |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1194799254 PECOS PAC ID: 1951352517 Enrollment ID: I20050201000868 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Darci J Wall |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1104898303 PECOS PAC ID: 9830140490 Enrollment ID: I20050201000895 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Naoki Takahashi |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1891774261 PECOS PAC ID: 8325091507 Enrollment ID: I20050228000852 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joel A Bobby |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1770569907 PECOS PAC ID: 2567416670 Enrollment ID: I20050310000609 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jolanta M Durski |
|---|---|
| Provider Type | Practitioner - Nuclear Medicine |
| Provider Identifiers | NPI Number: 1407820780 PECOS PAC ID: 5698720472 Enrollment ID: I20050315000151 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Chad J Fleming |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1841276854 PECOS PAC ID: 9032164587 Enrollment ID: I20050317000154 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jon M Bylander |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1578540555 PECOS PAC ID: 2163469966 Enrollment ID: I20050413000672 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel L Price |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1316926587 PECOS PAC ID: 8820036015 Enrollment ID: I20050419000633 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David A Foley |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1699751610 PECOS PAC ID: 3577502988 Enrollment ID: I20050426000678 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Seema Maddali |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1467498972 PECOS PAC ID: 7810944246 Enrollment ID: I20050502001014 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sophie J Bakri |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1861464455 PECOS PAC ID: 2466492608 Enrollment ID: I20050506000763 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicole K Anderson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1952373458 PECOS PAC ID: 9638110018 Enrollment ID: I20050516000796 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anthony F Chou |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1780646778 PECOS PAC ID: 5294776084 Enrollment ID: I20050523000339 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel Richard Dockham |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1932270758 PECOS PAC ID: 5395632830 Enrollment ID: I20050523000446 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ognjen Gajic |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1194703967 PECOS PAC ID: 0244272060 Enrollment ID: I20050523000686 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian L Whited |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457312662 PECOS PAC ID: 3274434139 Enrollment ID: I20050524000540 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Molly A Feely |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1992755151 PECOS PAC ID: 9638139959 Enrollment ID: I20050602000103 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric R Niendorf |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1780685404 PECOS PAC ID: 2567414121 Enrollment ID: I20050603000500 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Minerva Johnson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1962473058 PECOS PAC ID: 6406899111 Enrollment ID: I20050603000532 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian T Malyon |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629043070 PECOS PAC ID: 5890788962 Enrollment ID: I20050608000478 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark R Ciota |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1184603581 PECOS PAC ID: 2466496815 Enrollment ID: I20050616000073 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas W Nordahl |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1376500959 PECOS PAC ID: 0749226496 Enrollment ID: I20050701000915 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carl H Rose |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1780662114 PECOS PAC ID: 8628014156 Enrollment ID: I20050706000384 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rowlens M Melduni |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1285614362 PECOS PAC ID: 8325074073 Enrollment ID: I20050713000910 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Fawad Qureshi |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1306829882 PECOS PAC ID: 6103853387 Enrollment ID: I20050719001114 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert C Albright |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1417934738 PECOS PAC ID: 0749217768 Enrollment ID: I20050721000436 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John W Hildebrandt |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1255305884 PECOS PAC ID: 6608803549 Enrollment ID: I20050721000657 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael T Eckstrom |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1841279197 PECOS PAC ID: 8325076177 Enrollment ID: I20050802000694 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew A Frick |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1245203777 PECOS PAC ID: 8921036682 Enrollment ID: I20050803000131 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John A Grzybowski |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1679552038 PECOS PAC ID: 1658309323 Enrollment ID: I20050803000211 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jason A Post |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1144208364 PECOS PAC ID: 2466480132 Enrollment ID: I20050803000220 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rhonda K Hemann |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710966072 PECOS PAC ID: 7810926409 Enrollment ID: I20050804000165 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alice A Schrad |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1336128511 PECOS PAC ID: 1355370982 Enrollment ID: I20050804000449 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Leonard Shelhamer |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1053390245 PECOS PAC ID: 9032180005 Enrollment ID: I20050804000477 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Judy J Sibilrud |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720067911 PECOS PAC ID: 8921037565 Enrollment ID: I20050804000507 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Della K Simmons |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1730168923 PECOS PAC ID: 7214966860 Enrollment ID: I20050804000585 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Leonid Skorin |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1710966908 PECOS PAC ID: 0749219392 Enrollment ID: I20050804000602 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mieca S Valen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386623585 PECOS PAC ID: 8325077977 Enrollment ID: I20050804000652 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adam J Weisbrod |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1992785182 PECOS PAC ID: 8527097724 Enrollment ID: I20050808001195 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nandan S Anavekar |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1760456453 PECOS PAC ID: 8224067434 Enrollment ID: I20050808001240 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lily C Wong-kisiel |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1336111855 PECOS PAC ID: 7113956137 Enrollment ID: I20050810000712 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nathaniel W Taggart |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1073593877 PECOS PAC ID: 9133158058 Enrollment ID: I20050810000788 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher H Hunt |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1073545117 PECOS PAC ID: 7517997968 Enrollment ID: I20050816000737 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas A Foley |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1447220835 PECOS PAC ID: 3072543370 Enrollment ID: I20050816001163 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Richard A Oeckler |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1497733521 PECOS PAC ID: 7719919620 Enrollment ID: I20050831000296 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John W Askew |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1568436632 PECOS PAC ID: 2567494073 Enrollment ID: I20050906000839 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mithri R Junna |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1265405922 PECOS PAC ID: 1951335967 Enrollment ID: I20050920000523 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lynne M Lillie |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1811938376 PECOS PAC ID: 4981638525 Enrollment ID: I20050922000602 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Miguel A Park |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1619940483 PECOS PAC ID: 7416941687 Enrollment ID: I20051010000824 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Crystal R Bonnichsen |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1730151259 PECOS PAC ID: 5294750063 Enrollment ID: I20051011000367 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Roger Shepherd |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1801875075 PECOS PAC ID: 5193740603 Enrollment ID: I20051013000085 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Peggy V Dunton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578597407 PECOS PAC ID: 0547287666 Enrollment ID: I20051028000105 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy S Ettore |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1376521609 PECOS PAC ID: 4082631841 Enrollment ID: I20051031000893 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shellie Lynette Thompson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1316034903 PECOS PAC ID: 0547288516 Enrollment ID: I20051108000688 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Richard L Wood |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1104805340 PECOS PAC ID: 7517986755 Enrollment ID: I20051116000660 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carol A Minzel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659309342 PECOS PAC ID: 3375563497 Enrollment ID: I20051202000649 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert P Maddock |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1679528483 PECOS PAC ID: 6901889716 Enrollment ID: I20051205000500 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sumit Bhagra |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1982684817 PECOS PAC ID: 6901827013 Enrollment ID: I20051215000771 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joerg Herrmann |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1295713253 PECOS PAC ID: 0042232282 Enrollment ID: I20051230000546 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dawn T Ritter |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275594483 PECOS PAC ID: 3375566482 Enrollment ID: I20060104000322 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Norman Davies |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1174593941 PECOS PAC ID: 7517980907 Enrollment ID: I20060111001208 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Benjamin W Eidem |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1306869433 PECOS PAC ID: 5496641052 Enrollment ID: I20060118000983 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kellyanna J Moore |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1538120746 PECOS PAC ID: 3779597430 Enrollment ID: I20060201000764 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James L Leenstra |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1174593982 PECOS PAC ID: 4284649120 Enrollment ID: I20060214000039 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert C Murphy |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1962482737 PECOS PAC ID: 1850306762 Enrollment ID: I20060214000574 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hector Michelena |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1861469744 PECOS PAC ID: 4688689300 Enrollment ID: I20060215000828 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adelaide M Arruda-olson |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1053388934 PECOS PAC ID: 2961417597 Enrollment ID: I20060217000324 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher J Ball |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1467408625 PECOS PAC ID: 3173539012 Enrollment ID: I20060301000379 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Richard E Mayerchak |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1568417806 PECOS PAC ID: 6901813195 Enrollment ID: I20060313000656 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Deborah L Abney-lidahl |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1053386458 PECOS PAC ID: 5991606261 Enrollment ID: I20060404000597 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David W Bahl |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1912974569 PECOS PAC ID: 6406864305 Enrollment ID: I20060404000621 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Marc E Bettich |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1851367213 PECOS PAC ID: 3678582319 Enrollment ID: I20060407000440 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian P Coyle |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1598732836 PECOS PAC ID: 2365451002 Enrollment ID: I20060407000469 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy A Dejong |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467427427 PECOS PAC ID: 1153330899 Enrollment ID: I20060407000503 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Everett M Hughes |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1710952718 PECOS PAC ID: 8527077106 Enrollment ID: I20060410000265 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gregory A Kays |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1093780439 PECOS PAC ID: 9537178132 Enrollment ID: I20060410000453 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeffrey M Ketcham |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1326013772 PECOS PAC ID: 8426067026 Enrollment ID: I20060410000472 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas M Meyer |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1821064700 PECOS PAC ID: 2264441815 Enrollment ID: I20060411000234 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric C Mollgaard |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1083681647 PECOS PAC ID: 0042229601 Enrollment ID: I20060411000258 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nancy R Olson |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1184699050 PECOS PAC ID: 4284643750 Enrollment ID: I20060411000463 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer M Radtke |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1316912793 PECOS PAC ID: 9537178025 Enrollment ID: I20060411000539 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric John Schnaith |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1649245952 PECOS PAC ID: 5294744793 Enrollment ID: I20060411000590 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Susan T Seykora |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1912982653 PECOS PAC ID: 2567471907 Enrollment ID: I20060413000252 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert P Hartman |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1598742785 PECOS PAC ID: 6406865351 Enrollment ID: I20060420000444 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hector Ricardo Villarraga |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1376562546 PECOS PAC ID: 1658260567 Enrollment ID: I20060421000216 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kim Baldwin |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1205801610 PECOS PAC ID: 4880604289 Enrollment ID: I20060501000167 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian E Kelly |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1659341212 PECOS PAC ID: 4385530138 Enrollment ID: I20060510000481 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | William D Farrar |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1942263108 PECOS PAC ID: 2668483991 Enrollment ID: I20060525000149 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer L Pecina |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1730127606 PECOS PAC ID: 4385656388 Enrollment ID: I20060612000049 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gregory C Jones |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1427019637 PECOS PAC ID: 4385656842 Enrollment ID: I20060627000041 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James A Boles |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1093752412 PECOS PAC ID: 9335151547 Enrollment ID: I20060706000199 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Cory J Ingram |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1104887504 PECOS PAC ID: 2062427370 Enrollment ID: I20060801000216 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jonathan N Johnson |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1285648899 PECOS PAC ID: 0446253470 Enrollment ID: I20060814000078 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carl H Cramer |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1659392652 PECOS PAC ID: 5597768010 Enrollment ID: I20060822000457 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kannan Ramar |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1750393922 PECOS PAC ID: 6002819463 Enrollment ID: I20060824000521 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Geoffrey B Johnson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1346263407 PECOS PAC ID: 8224032669 Enrollment ID: I20060828000148 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katie N Hunt |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1225051311 PECOS PAC ID: 0547264772 Enrollment ID: I20060831000120 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bo E Madsen |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1740293380 PECOS PAC ID: 0547264517 Enrollment ID: I20060905000482 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sunil V Mankad |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1912908401 PECOS PAC ID: 5294739298 Enrollment ID: I20060906000152 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Susan M Moeschler |
|---|---|
| Provider Type | Practitioner - Interventional Pain Management |
| Provider Identifiers | NPI Number: 1578575346 PECOS PAC ID: 9931103884 Enrollment ID: I20060907000049 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Erica L Berven |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1215900477 PECOS PAC ID: 8729082375 Enrollment ID: I20060913000111 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Benjamin M Howe |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1578675138 PECOS PAC ID: 0547265944 Enrollment ID: I20060918000367 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David Lewis Levin |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1487663761 PECOS PAC ID: 1456356724 Enrollment ID: I20060919000528 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark A Frye |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1609892603 PECOS PAC ID: 0547266041 Enrollment ID: I20061005000420 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ziad El Zoghby |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1508963562 PECOS PAC ID: 1153327515 Enrollment ID: I20061009000301 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicole L Varela |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1619073301 PECOS PAC ID: 7214933407 Enrollment ID: I20061011000410 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew T Drake |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1790871713 PECOS PAC ID: 2365448594 Enrollment ID: I20061011000732 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gregg A Horras |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1811903842 PECOS PAC ID: 8628046661 Enrollment ID: I20061012000219 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Teresa Giya Albert |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1598776478 PECOS PAC ID: 7214931799 Enrollment ID: I20061025000174 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mohammed Yousufuddin |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1053408500 PECOS PAC ID: 7911904743 Enrollment ID: I20061108000453 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jay D Mitchell |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1811957566 PECOS PAC ID: 1456359280 Enrollment ID: I20061110000050 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Vivek N Iyer |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1295812808 PECOS PAC ID: 6103824420 Enrollment ID: I20061121000505 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ann L Leland |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447338884 PECOS PAC ID: 5092713289 Enrollment ID: I20061122000461 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tessa M Hessedal |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144381666 PECOS PAC ID: 7315949237 Enrollment ID: I20070206000475 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew Jon Guse |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1326197716 PECOS PAC ID: 3779685847 Enrollment ID: I20070220000232 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Evie L Christensen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578623831 PECOS PAC ID: 2668574476 Enrollment ID: I20070226000452 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Allison K Cabalka |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1720065220 PECOS PAC ID: 6800999079 Enrollment ID: I20070307000631 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Vuyisile T Nkomo |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1205808607 PECOS PAC ID: 9133223670 Enrollment ID: I20070322000540 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bohyun Kim |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1235258591 PECOS PAC ID: 3971607599 Enrollment ID: I20070409000236 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alfredo L Clavell |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1831177021 PECOS PAC ID: 7618071812 Enrollment ID: I20070509000293 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher Russi |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1902890973 PECOS PAC ID: 9830093129 Enrollment ID: I20070529000103 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Martin G Rodriguez-porcel |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1750356440 PECOS PAC ID: 5294832283 Enrollment ID: I20070529000118 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew James Schaefer |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1649324690 PECOS PAC ID: 5294835963 Enrollment ID: I20070710000804 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John H Haley |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1912983834 PECOS PAC ID: 6901906445 Enrollment ID: I20070712000285 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Farris K Timimi |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1063483436 PECOS PAC ID: 5698717643 Enrollment ID: I20070717000575 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David F Black |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1750369526 PECOS PAC ID: 0749381747 Enrollment ID: I20070720000317 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paul G Thacker |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1982815817 PECOS PAC ID: 8426159260 Enrollment ID: I20070724000603 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicole R Krueger |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1427161330 PECOS PAC ID: 1759482326 Enrollment ID: I20070726000271 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tim Lamer |
|---|---|
| Provider Type | Practitioner - Interventional Pain Management |
| Provider Identifiers | NPI Number: 1235126525 PECOS PAC ID: 8820033368 Enrollment ID: I20070728000009 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert T Fazzio |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1811192172 PECOS PAC ID: 4082715487 Enrollment ID: I20070730000638 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Larry A Binkovitz |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1801834775 PECOS PAC ID: 4284725326 Enrollment ID: I20070803000497 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael W Cullen |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1568589174 PECOS PAC ID: 2264523075 Enrollment ID: I20070808000755 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher Mccoy |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1033230792 PECOS PAC ID: 9234220682 Enrollment ID: I20070814000569 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nathan W Cummins |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1225108772 PECOS PAC ID: 2365534708 Enrollment ID: I20070815000520 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Vance T Lehman |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1639371669 PECOS PAC ID: 8921190232 Enrollment ID: I20070816000266 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher John Mcleod |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1871612010 PECOS PAC ID: 0042302309 Enrollment ID: I20070816000693 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paul Mckie |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1104945336 PECOS PAC ID: 8820181217 Enrollment ID: I20070830000267 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Suraj Kapa |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1811100118 PECOS PAC ID: 7618060252 Enrollment ID: I20070912000498 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hind Jawdat Fadel |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1407998107 PECOS PAC ID: 1456445741 Enrollment ID: I20070918000041 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert J Hyde |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1528187911 PECOS PAC ID: 1850485848 Enrollment ID: I20070921000172 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Patrick W O'leary |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1881672632 PECOS PAC ID: 1254425010 Enrollment ID: I20070924000690 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Steven J Engman |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1194944785 PECOS PAC ID: 7113012881 Enrollment ID: I20070926001209 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rekha Mankad |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1306846290 PECOS PAC ID: 5193618478 Enrollment ID: I20071005000399 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicole S Nipper |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003016940 PECOS PAC ID: 0840386629 Enrollment ID: I20071010000482 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tina C Small |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255537981 PECOS PAC ID: 8921194697 Enrollment ID: I20071011000485 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shannon N Zingula |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1154522423 PECOS PAC ID: 0244326643 Enrollment ID: I20071017000226 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Susan J Austin |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1942289897 PECOS PAC ID: 2860306891 Enrollment ID: I20071018000154 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Karen A Truitt |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1396867347 PECOS PAC ID: 0840386033 Enrollment ID: I20071018000845 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stacey A Rizza |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1598731606 PECOS PAC ID: 0143316190 Enrollment ID: I20071022000662 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adam T Froemming |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1588869846 PECOS PAC ID: 4587751441 Enrollment ID: I20071025000036 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jodi L Schulz |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1285614164 PECOS PAC ID: 3375630247 Enrollment ID: I20071025000162 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John M Knudsen |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1780664268 PECOS PAC ID: 2567559297 Enrollment ID: I20071029000120 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Erika L Halverson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679768956 PECOS PAC ID: 4082701289 Enrollment ID: I20071106000042 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gordon F Harms |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1982679577 PECOS PAC ID: 9133217011 Enrollment ID: I20071109000261 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy M Newman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942289863 PECOS PAC ID: 0941398531 Enrollment ID: I20071115000220 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas D Atwell |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1205801891 PECOS PAC ID: 2961591615 Enrollment ID: I20071203000356 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Peter Kalina |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1588644553 PECOS PAC ID: 9032209929 Enrollment ID: I20071215000059 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Henry C Pitot |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1700865102 PECOS PAC ID: 5698865947 Enrollment ID: I20071226000441 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | R Scott Wright |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1558333922 PECOS PAC ID: 8325141948 Enrollment ID: I20080109000494 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Grant D Schmit |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1043282064 PECOS PAC ID: 9335229889 Enrollment ID: I20080109000545 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Timothy Morgenthaler |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1043282585 PECOS PAC ID: 3779664420 Enrollment ID: I20080118000490 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert M Jacobson |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1790759728 PECOS PAC ID: 4385725092 Enrollment ID: I20080121000050 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kristen B Thomas |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1063492759 PECOS PAC ID: 9335220946 Enrollment ID: I20080121000105 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah C Sistek |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144419391 PECOS PAC ID: 3375625163 Enrollment ID: I20080201000242 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John A Skinner |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1437123809 PECOS PAC ID: 0941382741 Enrollment ID: I20080201000306 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Scott H Okuno |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1750367561 PECOS PAC ID: 2466535927 Enrollment ID: I20080207000383 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katherine Lf Clubb |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1386674208 PECOS PAC ID: 8325121163 Enrollment ID: I20080216000014 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Patricio Escalante |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1730115239 PECOS PAC ID: 0042394629 Enrollment ID: I20080220000496 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrew Stockland |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1336130426 PECOS PAC ID: 4587749205 Enrollment ID: I20080305000481 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ralph Thomas Tilbury |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1104804848 PECOS PAC ID: 0749385920 Enrollment ID: I20080306000649 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John G Park |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1386618312 PECOS PAC ID: 8325124951 Enrollment ID: I20080324000603 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel Seth Paley |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1326041674 PECOS PAC ID: 4082517255 Enrollment ID: I20080408000816 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy L Kotsenas |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1720079809 PECOS PAC ID: 6800973280 Enrollment ID: I20080409000527 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ronald S Kuzo |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1275524357 PECOS PAC ID: 0244318236 Enrollment ID: I20080416000143 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Margaret R Mcdonah |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1891767265 PECOS PAC ID: 1850479742 Enrollment ID: I20080417000232 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Martha Grogan |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1932188935 PECOS PAC ID: 8729167630 Enrollment ID: I20080505000083 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Theodore J Passe |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1881673218 PECOS PAC ID: 2769396464 Enrollment ID: I20080530000744 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lawrence R Keenan |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1225015472 PECOS PAC ID: 1355411331 Enrollment ID: I20080603000172 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jonathan Michael Hard |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1407906688 PECOS PAC ID: 3274631692 Enrollment ID: I20080702000436 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | William Mauck |
|---|---|
| Provider Type | Practitioner - Interventional Pain Management |
| Provider Identifiers | NPI Number: 1881667657 PECOS PAC ID: 7517039340 Enrollment ID: I20080710000393 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eun Jong Kim |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1487811782 PECOS PAC ID: 6608949292 Enrollment ID: I20080715000432 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alex Sneiders |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1629071675 PECOS PAC ID: 0648174672 Enrollment ID: I20080721000041 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Krishnaswamy Chandrasekaran |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1730169806 PECOS PAC ID: 5193822070 Enrollment ID: I20080722000099 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carrie M Carr |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1316125461 PECOS PAC ID: 2668546946 Enrollment ID: I20080805000178 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy L Brien |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1578743266 PECOS PAC ID: 4880768001 Enrollment ID: I20080806000687 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ann E Sneiders |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1245389451 PECOS PAC ID: 2365516283 Enrollment ID: I20080811000194 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian D Kim |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1386622421 PECOS PAC ID: 2062592546 Enrollment ID: I20080813000458 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Freddy Del-carpio Munoz |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1699938365 PECOS PAC ID: 9133294655 Enrollment ID: I20080819000213 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Malini Madhavan |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1538280680 PECOS PAC ID: 4587739958 Enrollment ID: I20080819000855 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew Carlson |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1831396712 PECOS PAC ID: 9234204611 Enrollment ID: I20080819000961 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Melissa C Lipford |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1760680615 PECOS PAC ID: 3971678038 Enrollment ID: I20080825000316 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hans P Sviggum |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1548420979 PECOS PAC ID: 0345315412 Enrollment ID: I20080825000392 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John J Schmitz |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1043470776 PECOS PAC ID: 6608941778 Enrollment ID: I20080825000399 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark E Morrey |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1750585501 PECOS PAC ID: 1153497029 Enrollment ID: I20080829000502 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeremy F Mcbride |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1093905861 PECOS PAC ID: 7618044298 Enrollment ID: I20080923000816 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paul S Floy |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1225004831 PECOS PAC ID: 2860577962 Enrollment ID: I20080925000103 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Erik K St Louis |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1922090851 PECOS PAC ID: 2264509439 Enrollment ID: I20080930000580 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark J Austin |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1225017098 PECOS PAC ID: 7810899549 Enrollment ID: I20081001000564 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy B Kolbe |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1295938009 PECOS PAC ID: 4880752187 Enrollment ID: I20081014000810 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Airika S Gibbs |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1821260761 PECOS PAC ID: 2860550019 Enrollment ID: I20081017000038 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rebecca Johnson |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1275794562 PECOS PAC ID: 2062471659 Enrollment ID: I20081023000860 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kenneth Olivier |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1063474245 PECOS PAC ID: 5890770630 Enrollment ID: I20081024000390 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kodjo M Bossou |
|---|---|
| Provider Type | Practitioner - Preventive Medicine |
| Provider Identifiers | NPI Number: 1982823951 PECOS PAC ID: 9032277579 Enrollment ID: I20081028000065 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eugen C Campian |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1740319003 PECOS PAC ID: 7618035197 Enrollment ID: I20081028000452 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeffrey B Geske |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1689878746 PECOS PAC ID: 4789743154 Enrollment ID: I20081030000579 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David A Steele |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487816872 PECOS PAC ID: 3678632767 Enrollment ID: I20081104000524 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Niti Rai Aggarwal |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1598962474 PECOS PAC ID: 3375602006 Enrollment ID: I20081110000378 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Richard H Rho |
|---|---|
| Provider Type | Practitioner - Interventional Pain Management |
| Provider Identifiers | NPI Number: 1467422667 PECOS PAC ID: 4981764321 Enrollment ID: I20081115000011 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian N Bartlett |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1790973782 PECOS PAC ID: 7113087438 Enrollment ID: I20081117000526 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ayse Karagulle Kendi |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1235358615 PECOS PAC ID: 3779644166 Enrollment ID: I20081203000718 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark S Collins |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1922070846 PECOS PAC ID: 9234290644 Enrollment ID: I20081203000921 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Omar F Abouezzeddine |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1740480391 PECOS PAC ID: 8123189545 Enrollment ID: I20081204000023 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Darcy L Reber |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023098886 PECOS PAC ID: 3072677160 Enrollment ID: I20090204000685 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert E Watson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1477523231 PECOS PAC ID: 9638234495 Enrollment ID: I20090211000810 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joel M Cassingham |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1245275460 PECOS PAC ID: 6002971611 Enrollment ID: I20090216000165 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anne-marie G Sykes |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1366422263 PECOS PAC ID: 2163588914 Enrollment ID: I20090304000148 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert A Wermers |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1952374407 PECOS PAC ID: 8123091725 Enrollment ID: I20090305000156 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Elice K Tiegs |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629213616 PECOS PAC ID: 7214093871 Enrollment ID: I20090305000471 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Margaret E Long |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1902885577 PECOS PAC ID: 3577629963 Enrollment ID: I20090310000522 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Debra S Coy |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124266325 PECOS PAC ID: 1052477296 Enrollment ID: I20090312000681 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Youssef F Maalouf |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1689649279 PECOS PAC ID: 9032133822 Enrollment ID: I20090317000241 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy K Widell |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1790790129 PECOS PAC ID: 0345307344 Enrollment ID: I20090318000487 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James R Gregoire |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1942272109 PECOS PAC ID: 8921165366 Enrollment ID: I20090330000258 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert J Houlihan |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1922086800 PECOS PAC ID: 5496802092 Enrollment ID: I20090420000131 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Deanne T Kashiwagi |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1588665806 PECOS PAC ID: 8628125119 Enrollment ID: I20090421000372 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tia M Stringer |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1114167608 PECOS PAC ID: 5294883674 Enrollment ID: I20090423000746 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Colleen R Nelson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902054836 PECOS PAC ID: 9436207354 Enrollment ID: I20090504000432 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Peter B Ryan Reichert |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1104069988 PECOS PAC ID: 7315096740 Enrollment ID: I20090514000260 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mila Berdecia |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1972549970 PECOS PAC ID: 4981684206 Enrollment ID: I20090608000295 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hugh Scott Smith |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1275617607 PECOS PAC ID: 9931168234 Enrollment ID: I20090625000045 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kim I Wilkerson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1558510693 PECOS PAC ID: 1254493281 Enrollment ID: I20090716000102 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Derek R Johnson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1750508453 PECOS PAC ID: 2567514557 Enrollment ID: I20090722000668 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Edward L Ward |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1306889712 PECOS PAC ID: 8224076989 Enrollment ID: I20090806000354 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rebecca K Ameduri |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1861696569 PECOS PAC ID: 4688728116 Enrollment ID: I20090819000136 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Terry L Hunt |
|---|---|
| Provider Type | Practitioner - Interventional Pain Management |
| Provider Identifiers | NPI Number: 1659536639 PECOS PAC ID: 7416002381 Enrollment ID: I20090827000722 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Meghna P Mansukhani |
|---|---|
| Provider Type | Practitioner - Sleep Medicine |
| Provider Identifiers | NPI Number: 1558561506 PECOS PAC ID: 7517012016 Enrollment ID: I20090908000052 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert F Rea |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1689651689 PECOS PAC ID: 5597869800 Enrollment ID: I20090911000160 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sandra M. S. Herrmann |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1790964088 PECOS PAC ID: 1850447012 Enrollment ID: I20090914000461 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Emily M Daligga |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1881804755 PECOS PAC ID: 8224184338 Enrollment ID: I20090915000294 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Scott M Riester |
|---|---|
| Provider Type | Practitioner - Preventive Medicine |
| Provider Identifiers | NPI Number: 1700042710 PECOS PAC ID: 2860538493 Enrollment ID: I20091012000391 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jacob Brent Ekins |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1528212420 PECOS PAC ID: 5698812089 Enrollment ID: I20091015000686 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Charlotte S Van Dorn |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1912153040 PECOS PAC ID: 5991842171 Enrollment ID: I20091020000555 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tyler S Oesterle |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1003062795 PECOS PAC ID: 4183761323 Enrollment ID: I20091021000310 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Darrell B Newman |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1366698011 PECOS PAC ID: 6608913850 Enrollment ID: I20091021000358 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Timothy J Welch |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1750360731 PECOS PAC ID: 5395882492 Enrollment ID: I20091022000039 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adam C Brandl |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033342522 PECOS PAC ID: 4385781152 Enrollment ID: I20091027000698 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael D Ringler |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1285751776 PECOS PAC ID: 0345387122 Enrollment ID: I20091027000834 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katherine Y Le |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1740445220 PECOS PAC ID: 8325185101 Enrollment ID: I20091027000852 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jenna R Wheeler Anderson |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1851557094 PECOS PAC ID: 8022155787 Enrollment ID: I20091028000737 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jessica J Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639404098 PECOS PAC ID: 9335286004 Enrollment ID: I20091029000054 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bhanuprakesh Kolla |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1417156597 PECOS PAC ID: 6901943539 Enrollment ID: I20091029000698 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Marysia S Tweet |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1821254939 PECOS PAC ID: 4082751615 Enrollment ID: I20091029000703 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert J Mc Donald |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1184870156 PECOS PAC ID: 7113065517 Enrollment ID: I20091104000667 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Phillip M Young |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1801879192 PECOS PAC ID: 1456368646 Enrollment ID: I20091105000638 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sara Eckloff |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1104907286 PECOS PAC ID: 6507938792 Enrollment ID: I20091109000115 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shailly Dham |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1134367352 PECOS PAC ID: 0143368209 Enrollment ID: I20091110000333 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gregory J Hanson |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1598742306 PECOS PAC ID: 4587702477 Enrollment ID: I20091113000247 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mary H Rahrick |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1346200094 PECOS PAC ID: 5496656365 Enrollment ID: I20091118000217 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carl B Burkland |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1740470129 PECOS PAC ID: 4789723461 Enrollment ID: I20091209000660 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert A Lee |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1871572818 PECOS PAC ID: 8820138522 Enrollment ID: I20091210000300 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Muriel M Schornack |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1730152349 PECOS PAC ID: 4082754734 Enrollment ID: I20091210000695 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric C Tangalos |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1528045952 PECOS PAC ID: 2264572940 Enrollment ID: I20091211000228 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Warren Manyara |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1639330822 PECOS PAC ID: 2466593074 Enrollment ID: I20100105000228 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric J Storvick |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1841279833 PECOS PAC ID: 3971415373 Enrollment ID: I20100106000412 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael A Mahr |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1225016959 PECOS PAC ID: 5597806984 Enrollment ID: I20100107000344 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bradley D Lewis |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1720067499 PECOS PAC ID: 7214078609 Enrollment ID: I20100107000356 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael H Silber |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1194705525 PECOS PAC ID: 0446391460 Enrollment ID: I20100112000589 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Darcy Ann Reed |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1104898444 PECOS PAC ID: 3173435252 Enrollment ID: I20100112000632 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Casey R Caldwell |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1356327696 PECOS PAC ID: 9032250923 Enrollment ID: I20100114000475 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew E Bernard |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1831163732 PECOS PAC ID: 4284775172 Enrollment ID: I20100114000491 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David W Claypool |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1013982172 PECOS PAC ID: 5193867083 Enrollment ID: I20100114000588 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James H Bower |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1730166513 PECOS PAC ID: 9830231588 Enrollment ID: I20100119000706 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Heidi M Connolly |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1689653891 PECOS PAC ID: 7113069683 Enrollment ID: I20100121000377 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Norbert G Campeau |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1811975121 PECOS PAC ID: 6103968680 Enrollment ID: I20100121000392 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert Mcbane |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1871579862 PECOS PAC ID: 5991847485 Enrollment ID: I20100121000524 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Claire E Bender |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1992777528 PECOS PAC ID: 1254243744 Enrollment ID: I20100121000678 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert J Witte |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1720067770 PECOS PAC ID: 1456493972 Enrollment ID: I20100121000828 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Diane E Schoeneman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1548221757 PECOS PAC ID: 8820130263 Enrollment ID: I20100122000272 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Horng H Chen |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1073599320 PECOS PAC ID: 0941342331 Enrollment ID: I20100122000663 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Steven R Alberts |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1780660209 PECOS PAC ID: 1254473648 Enrollment ID: I20100122000711 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert B Mccully |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1811969827 PECOS PAC ID: 3577666189 Enrollment ID: I20100125000303 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Douglas A Collins |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1083689483 PECOS PAC ID: 0244257178 Enrollment ID: I20100125000396 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Panithaya Chareonthaitawee |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1730165770 PECOS PAC ID: 6103968474 Enrollment ID: I20100125000504 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer Horn |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1215900436 PECOS PAC ID: 6608918719 Enrollment ID: I20100127000357 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John Huston |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1295711257 PECOS PAC ID: 2769524875 Enrollment ID: I20100127000391 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stephanie F Heller |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1750368692 PECOS PAC ID: 2961544903 Enrollment ID: I20100128000698 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jon O Ebbert |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1952388423 PECOS PAC ID: 6406998467 Enrollment ID: I20100128000817 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kaiser G Lim |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1457338725 PECOS PAC ID: 5799828752 Enrollment ID: I20100130000203 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gary M Miller |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1669459715 PECOS PAC ID: 8527054378 Enrollment ID: I20100130000283 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John D Port |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1902877657 PECOS PAC ID: 3072656040 Enrollment ID: I20100130000314 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joseph W Furst |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1184604662 PECOS PAC ID: 4981747805 Enrollment ID: I20100201000434 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Julie R Gilbertson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1497733273 PECOS PAC ID: 6103969068 Enrollment ID: I20100201000807 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas E Hartman |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1801873658 PECOS PAC ID: 2264575133 Enrollment ID: I20100202000127 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hon-chi Lee |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1477526101 PECOS PAC ID: 8628088317 Enrollment ID: I20100202000806 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Val Lowe |
|---|---|
| Provider Type | Practitioner - Nuclear Medicine |
| Provider Identifiers | NPI Number: 1730166885 PECOS PAC ID: 8921141763 Enrollment ID: I20100202000819 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kika M Dudiak |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1740269240 PECOS PAC ID: 0345383006 Enrollment ID: I20100203000090 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bonnie J Huppert |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1538132113 PECOS PAC ID: 8426191198 Enrollment ID: I20100203000205 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James F Glockner |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1861470817 PECOS PAC ID: 3375686041 Enrollment ID: I20100203000256 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Donald J Hagler |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1942206016 PECOS PAC ID: 4587617386 Enrollment ID: I20100203000633 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael D Ulrich |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1114907961 PECOS PAC ID: 8729121454 Enrollment ID: I20100203000745 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Edward P Lindell |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1285606285 PECOS PAC ID: 1254474984 Enrollment ID: I20100203000770 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas W. Rooke |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1003893306 PECOS PAC ID: 2668575416 Enrollment ID: I20100203000825 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David A Froehling |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1285613497 PECOS PAC ID: 6608919352 Enrollment ID: I20100203000876 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Raymond R Auger |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1497725519 PECOS PAC ID: 0446265086 Enrollment ID: I20100203000899 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Haraldur Bjarnason |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1164493540 PECOS PAC ID: 9032252788 Enrollment ID: I20100203000910 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Harry J Cloft |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1770553992 PECOS PAC ID: 4284777939 Enrollment ID: I20100203000937 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Irene G Sia |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1710950969 PECOS PAC ID: 4587707021 Enrollment ID: I20100204000913 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Timothy R Aksamit |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1184694770 PECOS PAC ID: 8527101963 Enrollment ID: I20100206000153 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark C Adkins |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1659359321 PECOS PAC ID: 3678616851 Enrollment ID: I20100210000514 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John J Dillon |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1932186996 PECOS PAC ID: 5799828992 Enrollment ID: I20100210000725 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David W Ivance |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1942261169 PECOS PAC ID: 7214070333 Enrollment ID: I20100211000205 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Steve Robert Ommen |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1639141559 PECOS PAC ID: 8325095383 Enrollment ID: I20100211000301 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric J Olson |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1225000722 PECOS PAC ID: 1355485400 Enrollment ID: I20100212000673 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gregory A Wiseman |
|---|---|
| Provider Type | Practitioner - Nuclear Medicine |
| Provider Identifiers | NPI Number: 1205816329 PECOS PAC ID: 9537203534 Enrollment ID: I20100215000107 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Darcy L Adamczyk |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1679559264 PECOS PAC ID: 0143364141 Enrollment ID: I20100215000147 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Patricia A Pellikka |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1316926546 PECOS PAC ID: 6204827199 Enrollment ID: I20100216000578 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paul M Huddleston |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1548249493 PECOS PAC ID: 6800930512 Enrollment ID: I20100218000756 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Deepi G Goyal |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1609853902 PECOS PAC ID: 5890839500 Enrollment ID: I20100218000771 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christine U C Lee |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1063484095 PECOS PAC ID: 8325182041 Enrollment ID: I20100218000809 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Titus C Evans |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1437137213 PECOS PAC ID: 7214071935 Enrollment ID: I20100218000829 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John I Lane |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1730159955 PECOS PAC ID: 4486629151 Enrollment ID: I20100218000834 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Allan Jaffe |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1538146626 PECOS PAC ID: 8426192147 Enrollment ID: I20100218000890 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Garvan C Kane |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1346214509 PECOS PAC ID: 0244374965 Enrollment ID: I20100218000892 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David M Hough |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1982679049 PECOS PAC ID: 3971647603 Enrollment ID: I20100218000894 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sandra Kopp |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1124090147 PECOS PAC ID: 5991849531 Enrollment ID: I20100219000202 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gina K Hesley |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1598744153 PECOS PAC ID: 3173667722 Enrollment ID: I20100219000316 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michele A Hanson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1154308187 PECOS PAC ID: 7618011131 Enrollment ID: I20100222000934 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kirk R Dornfeld |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467412114 PECOS PAC ID: 6507900024 Enrollment ID: I20100222000956 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark R Hansen |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1376529156 PECOS PAC ID: 9931243292 Enrollment ID: I20100224000591 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sandra J Taler |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1447222682 PECOS PAC ID: 0345384640 Enrollment ID: I20100224000967 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gurinder Vasdev |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1033198684 PECOS PAC ID: 4880653401 Enrollment ID: I20100224001004 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jill M Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841520988 PECOS PAC ID: 7719021922 Enrollment ID: I20100225000197 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jarrett W Richardson |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1104806744 PECOS PAC ID: 1557368792 Enrollment ID: I20100225000974 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Allen T Huang |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1083674733 PECOS PAC ID: 1052456126 Enrollment ID: I20100302000110 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Charlotte H Rydberg |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1184604613 PECOS PAC ID: 3971648999 Enrollment ID: I20100302000694 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joel G Fletcher |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1912975368 PECOS PAC ID: 6507901527 Enrollment ID: I20100302000714 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jason T Wray-raabolle |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457311102 PECOS PAC ID: 5597846030 Enrollment ID: I20100303000770 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael S Schoeneman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1639130842 PECOS PAC ID: 4486799319 Enrollment ID: I20100303000827 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Phillip A Kaupa |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1902866650 PECOS PAC ID: 7911042841 Enrollment ID: I20100303000854 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Scott A Bangs |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1912967662 PECOS PAC ID: 2264451152 Enrollment ID: I20100304000630 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Miguel E Mulet |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1891755542 PECOS PAC ID: 9234210774 Enrollment ID: I20100304000703 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael J Osborn |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1316927254 PECOS PAC ID: 0749325488 Enrollment ID: I20100304000993 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sean Caples |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1417929449 PECOS PAC ID: 2668517319 Enrollment ID: I20100304001101 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Doris Wenger |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1033198163 PECOS PAC ID: 5294870945 Enrollment ID: I20100304001104 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John T Wald |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1346210218 PECOS PAC ID: 3375688021 Enrollment ID: I20100304001114 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Raymond C Shields |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1710950472 PECOS PAC ID: 6204971963 Enrollment ID: I20100305000089 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark H Ereth |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1568448629 PECOS PAC ID: 9638118524 Enrollment ID: I20100305000255 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Reinhold Plate |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1639139389 PECOS PAC ID: 3274678966 Enrollment ID: I20100305000361 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian E Bunkers |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1558322768 PECOS PAC ID: 8022919992 Enrollment ID: I20100305000372 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah C Gantert |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1992765648 PECOS PAC ID: 8628113313 Enrollment ID: I20100305000382 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sanjay Misra |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1427035377 PECOS PAC ID: 3476698085 Enrollment ID: I20100308000431 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lawrence J Sinak |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1346228715 PECOS PAC ID: 2163567603 Enrollment ID: I20100308000792 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark A Nathan |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1992783369 PECOS PAC ID: 4688719131 Enrollment ID: I20100308000910 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Francisco Lopez-jimenez |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1467430371 PECOS PAC ID: 0042355596 Enrollment ID: I20100308000914 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert P Frantz |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1730153503 PECOS PAC ID: 6800999517 Enrollment ID: I20100308000956 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jorge F Quevedo |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1154300226 PECOS PAC ID: 6800814807 Enrollment ID: I20100309000311 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carol J Winter |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1871554089 PECOS PAC ID: 0941101810 Enrollment ID: I20100309000869 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Yongmei Cha |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1811973027 PECOS PAC ID: 5597655738 Enrollment ID: I20100311000090 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel A Diedrich |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1831179530 PECOS PAC ID: 9830189448 Enrollment ID: I20100311000104 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bradley J Erickson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1265411748 PECOS PAC ID: 1153456496 Enrollment ID: I20100311001058 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeanne M Huddleston |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1053384529 PECOS PAC ID: 5799810925 Enrollment ID: I20100312000902 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew R Callstrom |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1316925621 PECOS PAC ID: 3870628837 Enrollment ID: I20100316000242 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sheri L Reed |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1902870801 PECOS PAC ID: 5294860276 Enrollment ID: I20100316000479 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jae K Oh |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1366429946 PECOS PAC ID: 7214957315 Enrollment ID: I20100316000956 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kimberly K Amrami |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1508836511 PECOS PAC ID: 6002941044 Enrollment ID: I20100316001029 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Philip A Araoz |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1629042866 PECOS PAC ID: 8729113766 Enrollment ID: I20100316001035 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeff L Fidler |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1780661702 PECOS PAC ID: 1355476391 Enrollment ID: I20100316001046 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katrina N Glazebrook |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1437124872 PECOS PAC ID: 8527193481 Enrollment ID: I20100317000246 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kent H Rehfeldt |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1679550776 PECOS PAC ID: 3476688219 Enrollment ID: I20100317001123 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John M Barlow |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1811960115 PECOS PAC ID: 7618002478 Enrollment ID: I20100318000159 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Karina A Keogh |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1356315121 PECOS PAC ID: 7416082144 Enrollment ID: I20100318000930 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Torrey A Laack |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1114904224 PECOS PAC ID: 9032244769 Enrollment ID: I20100318000952 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David R Delone |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1144207325 PECOS PAC ID: 4385779016 Enrollment ID: I20100318000962 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric Moore |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1689653842 PECOS PAC ID: 6901931633 Enrollment ID: I20100318000980 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrew G Moore |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1770560666 PECOS PAC ID: 1456486182 Enrollment ID: I20100318000984 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Grant D Heslep |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1174583827 PECOS PAC ID: 2769517242 Enrollment ID: I20100323000481 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel M Breitkopf |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1558420968 PECOS PAC ID: 8729113691 Enrollment ID: I20100323000992 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lyle J Olson |
|---|---|
| Provider Type | Practitioner - Advanced Heart Failure And Transplant Cardiology |
| Provider Identifiers | NPI Number: 1477525871 PECOS PAC ID: 0244331429 Enrollment ID: I20100324001186 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian J Bartholmai |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1609856830 PECOS PAC ID: 2668508896 Enrollment ID: I20100326000929 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kirk M Welker |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1497734594 PECOS PAC ID: 6103864590 Enrollment ID: I20100327000163 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John W Wilson |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1780654830 PECOS PAC ID: 9032245915 Enrollment ID: I20100330000977 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eelco Wijdicks |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1831177765 PECOS PAC ID: 3779619416 Enrollment ID: I20100331001265 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Peter A Smars |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1851371421 PECOS PAC ID: 6406983923 Enrollment ID: I20100414000860 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rebecca M Lindell |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1992778344 PECOS PAC ID: 8527195932 Enrollment ID: I20100415000965 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paul Friedman |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1609855881 PECOS PAC ID: 3779610118 Enrollment ID: I20100416000307 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert L Collier |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1942285580 PECOS PAC ID: 3870620107 Enrollment ID: I20100419000651 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sara R Vande Kieft |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1306821939 PECOS PAC ID: 8224165568 Enrollment ID: I20100419000675 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Pierre A Rioux |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1164406807 PECOS PAC ID: 5395872592 Enrollment ID: I20100420000578 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Scott A Holtz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1588648174 PECOS PAC ID: 4082741293 Enrollment ID: I20100420000731 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gary L Schwartz |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1790758399 PECOS PAC ID: 5294862421 Enrollment ID: I20100420000964 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ann E Kearns |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1699745877 PECOS PAC ID: 9335284553 Enrollment ID: I20100422000859 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kyle W Klarich |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1497727945 PECOS PAC ID: 4385771385 Enrollment ID: I20100422001125 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mary J Kasten |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1871572842 PECOS PAC ID: 4688701469 Enrollment ID: I20100427000764 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Patrick Luetmer |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1316923378 PECOS PAC ID: 4284762865 Enrollment ID: I20100503000861 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Warren R Stanchfield |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1144204827 PECOS PAC ID: 9931237005 Enrollment ID: I20100511000446 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher P Wood |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1366421752 PECOS PAC ID: 7012045917 Enrollment ID: I20100513001029 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gerald W Volcheck |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1326028812 PECOS PAC ID: 9234268962 Enrollment ID: I20100518000867 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rosalie Jb Ivers |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1801861695 PECOS PAC ID: 7113056722 Enrollment ID: I20100519000971 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Karl N Krecke |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1376513416 PECOS PAC ID: 3072642693 Enrollment ID: I20100520000071 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tara L Henrichsen |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1245216464 PECOS PAC ID: 5799814315 Enrollment ID: I20100520000094 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amer N Kalaaji |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1790756302 PECOS PAC ID: 9739218363 Enrollment ID: I20100520000169 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Vincent J Canzanello |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1386620771 PECOS PAC ID: 7113056607 Enrollment ID: I20100520001054 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ann T Sadosty |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1649250168 PECOS PAC ID: 2961531033 Enrollment ID: I20100527000718 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Judy L Fruehbrodt-glenzinski |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1649204645 PECOS PAC ID: 2567591647 Enrollment ID: I20100527000774 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas G Howell |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1912925223 PECOS PAC ID: 7315094828 Enrollment ID: I20100602000950 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel Borgeson |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1033183520 PECOS PAC ID: 7719940477 Enrollment ID: I20100605000186 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Norman E Torres |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1356321541 PECOS PAC ID: 1254461031 Enrollment ID: I20100605000203 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric B Farnberg |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1760492052 PECOS PAC ID: 3375530538 Enrollment ID: I20100610000731 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Maja Tippman-peikert |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1497727622 PECOS PAC ID: 4385775212 Enrollment ID: I20100621000924 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bernard Aoun |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1194925305 PECOS PAC ID: 4183756828 Enrollment ID: I20100716000094 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brendan P Mcmenomy |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1326230798 PECOS PAC ID: 6103959754 Enrollment ID: I20100803000335 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Raj Palraj |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1225203201 PECOS PAC ID: 7517090079 Enrollment ID: I20100804000404 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jared T Verdoorn |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1639309727 PECOS PAC ID: 8628101193 Enrollment ID: I20100804000527 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael L Wells |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1013147263 PECOS PAC ID: 4981737459 Enrollment ID: I20100804000545 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Emily C Bendel |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1144457730 PECOS PAC ID: 9931233012 Enrollment ID: I20100811000190 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ivaylo L Krastev |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1205073848 PECOS PAC ID: 9335273465 Enrollment ID: I20100811000807 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew G Pollema |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1427131895 PECOS PAC ID: 0648320994 Enrollment ID: I20100811000938 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John P Bois |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1295966430 PECOS PAC ID: 5597899823 Enrollment ID: I20100823000191 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ashley E Sievers |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1699905489 PECOS PAC ID: 1759415086 Enrollment ID: I20100823000213 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kimberly Beckstrom |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821315854 PECOS PAC ID: 6406970748 Enrollment ID: I20100824000543 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tyler J Peterson |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1639328784 PECOS PAC ID: 7517081870 Enrollment ID: I20100824000773 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David Morgan Penn |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1982822540 PECOS PAC ID: 6901985753 Enrollment ID: I20100826000242 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alastair J. S. Mckean |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1174753867 PECOS PAC ID: 2163546284 Enrollment ID: I20100826000456 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah L Davis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083932487 PECOS PAC ID: 3173648599 Enrollment ID: I20100908001037 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mariel Rivera |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1710180971 PECOS PAC ID: 1254456577 Enrollment ID: I20100909001198 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adam C Johnson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1467683987 PECOS PAC ID: 6305961624 Enrollment ID: I20100909001260 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Erik B Sviggum |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1114157369 PECOS PAC ID: 7810012622 Enrollment ID: I20100916001344 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel John Thompson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1386776961 PECOS PAC ID: 8224154372 Enrollment ID: I20100925000251 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Angus Scott Marshall |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1962483065 PECOS PAC ID: 6002877040 Enrollment ID: I20100929001527 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brandon Yuan |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1205064284 PECOS PAC ID: 6002008141 Enrollment ID: I20101007001387 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joseph H Skalski |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1548499759 PECOS PAC ID: 5991997736 Enrollment ID: I20101012000246 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Melanie A Hansen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083925325 PECOS PAC ID: 8325230030 Enrollment ID: I20101012001249 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David B Burkholder |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1598995722 PECOS PAC ID: 6305038027 Enrollment ID: I20101012001415 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bryan C Cannon |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1942380373 PECOS PAC ID: 2163592619 Enrollment ID: I20101013001232 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dante Schiavo |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1962632810 PECOS PAC ID: 6103018718 Enrollment ID: I20101013001260 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joseph E Rybar |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1457515553 PECOS PAC ID: 3375735988 Enrollment ID: I20101013001267 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gavin A Mckenzie |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1922234624 PECOS PAC ID: 7113110594 Enrollment ID: I20101018000921 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katie E Dease |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1417276155 PECOS PAC ID: 6305039280 Enrollment ID: I20101023000222 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James Patrick Klaas |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1861622375 PECOS PAC ID: 0143414698 Enrollment ID: I20101028001558 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael R Johnson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1972784056 PECOS PAC ID: 2062606148 Enrollment ID: I20101102001449 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeffery S Wheeler |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1407086291 PECOS PAC ID: 4880888981 Enrollment ID: I20101103000147 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark Stanley Mellstrom |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1346302106 PECOS PAC ID: 3577467844 Enrollment ID: I20101105001262 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stephen Broski |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1326282112 PECOS PAC ID: 1658566112 Enrollment ID: I20101109001584 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah I Scherger |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1588836704 PECOS PAC ID: 5193910545 Enrollment ID: I20101110001202 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Muhamad Elrashidi |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1164654232 PECOS PAC ID: 7517152994 Enrollment ID: I20101110001496 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adam W Amundson |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1588807911 PECOS PAC ID: 9436344322 Enrollment ID: I20101117001164 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Meera Krishnan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1104920776 PECOS PAC ID: 1557388568 Enrollment ID: I20101117001236 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Timothy D Vangelder |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1831334424 PECOS PAC ID: 1759446859 Enrollment ID: I20101130000793 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kristina J Rauenhorst |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1508992629 PECOS PAC ID: 5698962397 Enrollment ID: I20101207000989 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brandon P. Verdoorn |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1154550200 PECOS PAC ID: 3476740788 Enrollment ID: I20101213001104 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas C Gerber |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1538156799 PECOS PAC ID: 5698803500 Enrollment ID: I20110114000171 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Allison B Berg-heinemann |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689984569 PECOS PAC ID: 1355522301 Enrollment ID: I20110223000742 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexander W Stricker |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1205023686 PECOS PAC ID: 7214110667 Enrollment ID: I20110323000488 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael D Sawyer |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1568774156 PECOS PAC ID: 5092998328 Enrollment ID: I20110324000463 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eduardo Antpack Filho |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1740439876 PECOS PAC ID: 6800070335 Enrollment ID: I20110407000720 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sunil S Khanna |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1033195797 PECOS PAC ID: 0244414795 Enrollment ID: I20110407000893 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Autumn M Brogan |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1578729976 PECOS PAC ID: 8527242676 Enrollment ID: I20110413001041 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amber L Kraft |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417250218 PECOS PAC ID: 3678758216 Enrollment ID: I20110426000538 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jonathan Alleckson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1346547445 PECOS PAC ID: 8123203106 Enrollment ID: I20110506000696 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lindsey A Janzig |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538451398 PECOS PAC ID: 8729264098 Enrollment ID: I20110520000675 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michelle L Thompson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1912205576 PECOS PAC ID: 9032395330 Enrollment ID: I20110523000315 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Okechukwu N Osuebi |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1710146287 PECOS PAC ID: 1759568033 Enrollment ID: I20110614000640 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrea G Kattah |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1487815528 PECOS PAC ID: 3173700358 Enrollment ID: I20110616000205 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Maichel S Abou El Markarim Gharabway |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1871735936 PECOS PAC ID: 6103004734 Enrollment ID: I20110629000421 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher A Kasal |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1407034663 PECOS PAC ID: 4082892534 Enrollment ID: I20110701000347 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Fadi Yahya |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1285813329 PECOS PAC ID: 9638357908 Enrollment ID: I20110711000409 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ragna Adair Godtland |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1386958452 PECOS PAC ID: 0840489621 Enrollment ID: I20110722000702 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeremy Thaden |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1295996296 PECOS PAC ID: 3971771577 Enrollment ID: I20110726000864 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jonathan P Erickson |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1134325475 PECOS PAC ID: 0446445886 Enrollment ID: I20110810000651 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Angela R Bentley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053501866 PECOS PAC ID: 5193817369 Enrollment ID: I20110816000564 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicole K Callahan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760779706 PECOS PAC ID: 0143499624 Enrollment ID: I20110818000268 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jesse T Young |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1558688077 PECOS PAC ID: 1850561101 Enrollment ID: I20110824000762 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark Smith |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1730490426 PECOS PAC ID: 0547430738 Enrollment ID: I20110825000415 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lyndsay D Viers |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1225349764 PECOS PAC ID: 5092985283 Enrollment ID: I20110825000421 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christin A Tiegs Heiden |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1164734000 PECOS PAC ID: 1759551955 Enrollment ID: I20110825000512 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Newton B Neidert |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1912226440 PECOS PAC ID: 2062683634 Enrollment ID: I20110913000155 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tara L Anderson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1871805044 PECOS PAC ID: 0143491688 Enrollment ID: I20110914000281 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carrie L Kern |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1013233709 PECOS PAC ID: 5991976375 Enrollment ID: I20110914000747 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bradley Aaron Bohn |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1326359241 PECOS PAC ID: 0648441832 Enrollment ID: I20110920000278 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Caroline J Von Bormann |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1790949626 PECOS PAC ID: 8628249869 Enrollment ID: I20110920000931 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jolene M Carlson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1982992350 PECOS PAC ID: 0143491233 Enrollment ID: I20110921000627 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher Desimone |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1326369935 PECOS PAC ID: 7012189608 Enrollment ID: I20111003000723 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Laura A Fisher |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1699088039 PECOS PAC ID: 1456523059 Enrollment ID: I20111003000760 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bernardo Selim |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1174501423 PECOS PAC ID: 9739151291 Enrollment ID: I20111004000419 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nila J Akhtar |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1366611345 PECOS PAC ID: 2961575253 Enrollment ID: I20111004000862 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Chi Wan Koo |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1285898361 PECOS PAC ID: 9234282989 Enrollment ID: I20111012000796 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ashley K Kimeu |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053690289 PECOS PAC ID: 8527230606 Enrollment ID: I20111014000113 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicole C Beatty |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1982657607 PECOS PAC ID: 2466542972 Enrollment ID: I20111017000669 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bradley F Thompson |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1902127640 PECOS PAC ID: 2567635634 Enrollment ID: I20111105000039 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Megan Johnston Flanders |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1033317730 PECOS PAC ID: 6103983911 Enrollment ID: I20111110000154 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brianna M Skrukrud |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174802151 PECOS PAC ID: 4183898083 Enrollment ID: I20111110000282 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kathryn M Van Abel |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1518288497 PECOS PAC ID: 2062686678 Enrollment ID: I20111116000930 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mansi Kanuga |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1588814016 PECOS PAC ID: 5890811913 Enrollment ID: I20111117000053 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stephanie Lorenson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710091459 PECOS PAC ID: 9032136320 Enrollment ID: I20111221000221 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Asha M J Madhar |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1902052632 PECOS PAC ID: 8527234129 Enrollment ID: I20120103000682 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Salvador Cardenas |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1255496568 PECOS PAC ID: 1355384710 Enrollment ID: I20120116000172 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer Lynn Goins |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1811024250 PECOS PAC ID: 1759558604 Enrollment ID: I20120118000534 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jodie M Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063797413 PECOS PAC ID: 5890954309 Enrollment ID: I20120301000756 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jonathan J Uy |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1467434985 PECOS PAC ID: 0143223834 Enrollment ID: I20120314000279 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sudhakar Venkatesh |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1679869390 PECOS PAC ID: 0446411771 Enrollment ID: I20120413000424 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David Moses |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1902171358 PECOS PAC ID: 2365603461 Enrollment ID: I20120417000727 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katherine M Jacobsen |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1730452046 PECOS PAC ID: 5698937456 Enrollment ID: I20120424000632 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Santosh Dhital |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1275762395 PECOS PAC ID: 6800050469 Enrollment ID: I20120611000398 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katie A Lindahl |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1679846869 PECOS PAC ID: 3375707839 Enrollment ID: I20120613000083 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Laura E Walker |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1770750390 PECOS PAC ID: 1254596703 Enrollment ID: I20120706000364 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Muhammad Yasir Qureshi |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1407065014 PECOS PAC ID: 3577719749 Enrollment ID: I20120804000048 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joshua P Froman |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1326201583 PECOS PAC ID: 0749436913 Enrollment ID: I20120804000058 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Siva K Mulpuru |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1770740417 PECOS PAC ID: 4284880352 Enrollment ID: I20120806000050 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Manish S Sharma |
|---|---|
| Provider Type | Practitioner - Neurosurgery |
| Provider Identifiers | NPI Number: 1134421282 PECOS PAC ID: 1658527734 Enrollment ID: I20120806000166 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nathan Charles Hull |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1689936171 PECOS PAC ID: 8022264878 Enrollment ID: I20120809000515 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jason H Anderson |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1336435270 PECOS PAC ID: 3274789052 Enrollment ID: I20120809000821 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stacey B Hanna |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316207822 PECOS PAC ID: 9830345628 Enrollment ID: I20120809000941 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David A Olsen |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1679868343 PECOS PAC ID: 6002062759 Enrollment ID: I20120810000744 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tucker Fulton Johnson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1467744706 PECOS PAC ID: 4688820343 Enrollment ID: I20120813000080 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rebekkah W Frunzac |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1033497169 PECOS PAC ID: 0547416265 Enrollment ID: I20120813000758 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joanne Cnp Mcgaffey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194085613 PECOS PAC ID: 9830346014 Enrollment ID: I20120822000668 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alex A Nagelschneider |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1033400031 PECOS PAC ID: 7517114705 Enrollment ID: I20120822000726 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Puneet D Narang |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1609021930 PECOS PAC ID: 3476700543 Enrollment ID: I20120823000971 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John Ohoro |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1659513364 PECOS PAC ID: 0840447785 Enrollment ID: I20120828000276 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian T Welch |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1740572080 PECOS PAC ID: 0749437531 Enrollment ID: I20120830000109 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Waleed Brinjikji |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1770879892 PECOS PAC ID: 9931356656 Enrollment ID: I20120830000521 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jessica Christine Schoen |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1417243783 PECOS PAC ID: 0042467540 Enrollment ID: I20120905000326 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Benjamin D Knutson |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1114248192 PECOS PAC ID: 3375790827 Enrollment ID: I20120906000047 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Julie B.w. Guerin |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1710270384 PECOS PAC ID: 5991952459 Enrollment ID: I20120906000191 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kenneth W Merrell |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1952693293 PECOS PAC ID: 1254589526 Enrollment ID: I20120911000252 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Cara Cockerill |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1033404082 PECOS PAC ID: 5092963272 Enrollment ID: I20120912000764 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anna B Strand |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467712638 PECOS PAC ID: 4688822877 Enrollment ID: I20120912000903 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hayan Jouni |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1417278987 PECOS PAC ID: 7911155130 Enrollment ID: I20120913000266 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher Joseph Reisenauer |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1811285588 PECOS PAC ID: 7214185230 Enrollment ID: I20120918000082 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Meghan E. Murphy |
|---|---|
| Provider Type | Practitioner - Neurosurgery |
| Provider Identifiers | NPI Number: 1992090385 PECOS PAC ID: 1951559806 Enrollment ID: I20120918000531 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Cameron R Wangsgard |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1831485564 PECOS PAC ID: 7618126228 Enrollment ID: I20120925000493 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kyle M Mckenzie |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1942595012 PECOS PAC ID: 7416106034 Enrollment ID: I20120925000645 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Narayan R Kissoon |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1194019307 PECOS PAC ID: 9931358579 Enrollment ID: I20120925000838 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ann T. P. Bender |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1114214822 PECOS PAC ID: 7517116874 Enrollment ID: I20121001000293 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Deena M Nasr |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1245529676 PECOS PAC ID: 0042469330 Enrollment ID: I20121002000155 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Darin B White |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1558617779 PECOS PAC ID: 4284883596 Enrollment ID: I20121002000329 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Donald Thor Buisman |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1770565533 PECOS PAC ID: 0749227494 Enrollment ID: I20121003000700 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hemang Yadav |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1891016549 PECOS PAC ID: 3971752197 Enrollment ID: I20121003000910 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Timothy D Krueger |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093076929 PECOS PAC ID: 0648429456 Enrollment ID: I20121010000394 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ammar Killu |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1790006658 PECOS PAC ID: 1355590068 Enrollment ID: I20121012000054 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joshua P Fenske |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861754764 PECOS PAC ID: 1355591629 Enrollment ID: I20121022000687 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicole Rae Pelach |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336499904 PECOS PAC ID: 9830349000 Enrollment ID: I20121024000286 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anita C Bissinger |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1033439484 PECOS PAC ID: 5193976397 Enrollment ID: I20121116000397 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amanda F Meyer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518220680 PECOS PAC ID: 8123279213 Enrollment ID: I20121120000141 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Danielle L Blazejak |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871848366 PECOS PAC ID: 6406007483 Enrollment ID: I20121126000125 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | William R Miranda |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1255652970 PECOS PAC ID: 5092966960 Enrollment ID: I20121127000585 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michele M Merten |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487915567 PECOS PAC ID: 7416109160 Enrollment ID: I20121204000379 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adam J Goble |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205195385 PECOS PAC ID: 0941452411 Enrollment ID: I20121207000179 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Heather J Obermeyer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447504014 PECOS PAC ID: 5092968123 Enrollment ID: I20130123000277 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paula A Abramovith Feijo |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1386653384 PECOS PAC ID: 1658377346 Enrollment ID: I20130220000574 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Trent David Anderson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1366751927 PECOS PAC ID: 8628223484 Enrollment ID: I20130227000376 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicholas G Rhodes |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1548466899 PECOS PAC ID: 5496919755 Enrollment ID: I20130604000532 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Allison D Christopoulos |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306187141 PECOS PAC ID: 1557500832 Enrollment ID: I20130617000728 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tobias Kummer |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1295950277 PECOS PAC ID: 3274657390 Enrollment ID: I20130705000405 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Wisit Cheungpasitporn |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1114248424 PECOS PAC ID: 9032359393 Enrollment ID: I20130709000818 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Megan B Meyers |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1568696573 PECOS PAC ID: 7618117920 Enrollment ID: I20130710000561 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Vanessa E Torbenson |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1033178280 PECOS PAC ID: 2769540277 Enrollment ID: I20130710000563 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James H Boyum |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1083877187 PECOS PAC ID: 1153584503 Enrollment ID: I20130711000346 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel B Grossman |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1699926881 PECOS PAC ID: 5890972152 Enrollment ID: I20130716000351 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tami E Mullenbach |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1841530193 PECOS PAC ID: 8729228622 Enrollment ID: I20130716000862 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mari Charisse B Trinidad |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1336386093 PECOS PAC ID: 3476717729 Enrollment ID: I20130723000205 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Peter Alexander Noseworthy |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1295704245 PECOS PAC ID: 5294732616 Enrollment ID: I20130724000823 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Scott G Perkinson |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1922263847 PECOS PAC ID: 4981845492 Enrollment ID: I20130725000868 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sean M Brennan |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1457559684 PECOS PAC ID: 3476608522 Enrollment ID: I20130726000463 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Chris Gu |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1134482581 PECOS PAC ID: 9739327479 Enrollment ID: I20130729001053 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bhavini H Carns |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1811180763 PECOS PAC ID: 6406097724 Enrollment ID: I20130730000431 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Theodore Hanson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1417211483 PECOS PAC ID: 1254577240 Enrollment ID: I20130806000839 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anthony L Fine |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1780946756 PECOS PAC ID: 5294971313 Enrollment ID: I20130806000842 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jason Allen Lee |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1003077223 PECOS PAC ID: 2668614298 Enrollment ID: I20130812000517 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sumedh S Hoskote |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1063724425 PECOS PAC ID: 2769624154 Enrollment ID: I20130814000756 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lara A Walkoff |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1588922231 PECOS PAC ID: 2668614884 Enrollment ID: I20130816000550 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sydney L Schone |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295176287 PECOS PAC ID: 9537302492 Enrollment ID: I20130826000736 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher L Welle |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1154677375 PECOS PAC ID: 0749423531 Enrollment ID: I20130826001089 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anne M Meehan |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1780024919 PECOS PAC ID: 5698918407 Enrollment ID: I20130827000315 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer M Martinez Thompson |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1518221415 PECOS PAC ID: 9436395548 Enrollment ID: I20130827000687 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Maya E Kessler |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1164786018 PECOS PAC ID: 2567608318 Enrollment ID: I20130828000726 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Abby L Levasseur |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700220068 PECOS PAC ID: 4284868399 Enrollment ID: I20131003000186 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kim Ann Reinitz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245662600 PECOS PAC ID: 2668606567 Enrollment ID: I20131008001781 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael D. Olson |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1477567576 PECOS PAC ID: 3476518739 Enrollment ID: I20131009000656 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ashok Seshadri |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1669662524 PECOS PAC ID: 4082848841 Enrollment ID: I20131009001853 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Josie K Hayes |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497196463 PECOS PAC ID: 4385878834 Enrollment ID: I20131016000833 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mary K Holm |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1477583664 PECOS PAC ID: 0446349153 Enrollment ID: I20131018000413 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Erik Scharrer |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1245525484 PECOS PAC ID: 5395983175 Enrollment ID: I20131028000275 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Maegen L Storm |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1982950341 PECOS PAC ID: 3779718820 Enrollment ID: I20131028001197 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jamie L Carroll |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043658057 PECOS PAC ID: 1254566227 Enrollment ID: I20131029000059 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joshua A Cochrane |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1962837849 PECOS PAC ID: 4688800949 Enrollment ID: I20131115001239 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Emad F Beshai |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1528069598 PECOS PAC ID: 3072614833 Enrollment ID: I20131126000188 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Angela N Tripp |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1770911562 PECOS PAC ID: 5991931776 Enrollment ID: I20131127000451 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Megan E Lynch |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760818009 PECOS PAC ID: 4284860917 Enrollment ID: I20131202000300 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy E Down |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1629053327 PECOS PAC ID: 9537057534 Enrollment ID: I20131205000674 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rachel M Wiste |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639509557 PECOS PAC ID: 2668609082 Enrollment ID: I20131210001727 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Elizabeth Claire Fogelson |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1568726099 PECOS PAC ID: 6901042977 Enrollment ID: I20140225001071 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Megan L Beck |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710302807 PECOS PAC ID: 7113158304 Enrollment ID: I20140402000140 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nichole A Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649695685 PECOS PAC ID: 8628200672 Enrollment ID: I20140407001119 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Randy M Foss |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1083903033 PECOS PAC ID: 0547403446 Enrollment ID: I20140415001283 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Wendy K Trihus |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1568542579 PECOS PAC ID: 8628025699 Enrollment ID: I20140429000188 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Patrick J Marsh |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1295957991 PECOS PAC ID: 1052406790 Enrollment ID: I20140501001095 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kissinger O Anusionwu |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1730510629 PECOS PAC ID: 0042443467 Enrollment ID: I20140508001623 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lee H Eckstein |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1619176187 PECOS PAC ID: 6002056801 Enrollment ID: I20140513001102 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Holly A Schenzel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578904355 PECOS PAC ID: 2567685886 Enrollment ID: I20140513002344 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katherine L Trelstad-andrist |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255742003 PECOS PAC ID: 9537383773 Enrollment ID: I20140610001160 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Abhishek J Deshmukh |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1538359906 PECOS PAC ID: 8325262454 Enrollment ID: I20140611002035 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Troy Seelhammer |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1447480694 PECOS PAC ID: 1355579376 Enrollment ID: I20140625000734 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kerry M Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487066304 PECOS PAC ID: 5890910087 Enrollment ID: I20140701002294 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Larry Deppe |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1982802815 PECOS PAC ID: 5496822322 Enrollment ID: I20140702001417 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jason K Panchamia |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1740505031 PECOS PAC ID: 4486879632 Enrollment ID: I20140702001946 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thoyaja Koritala |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1528354024 PECOS PAC ID: 4284887613 Enrollment ID: I20140708000935 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael R Moynagh |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1164779211 PECOS PAC ID: 0749437689 Enrollment ID: I20140709000236 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Philip L Wackel |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1982800645 PECOS PAC ID: 0345465183 Enrollment ID: I20140710001224 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tahir Mehmood |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1740571413 PECOS PAC ID: 9830314459 Enrollment ID: I20140715001286 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeffrey T Siewert |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1932513678 PECOS PAC ID: 5698991156 Enrollment ID: I20140718002103 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kogulavadanan Arumaithurai |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1114157856 PECOS PAC ID: 6103042247 Enrollment ID: I20140724002535 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Harold J Hellweg |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1790071231 PECOS PAC ID: 3375769185 Enrollment ID: I20140730001973 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Seth A Schulz |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1235404609 PECOS PAC ID: 1557588258 Enrollment ID: I20140804000757 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alisa S Eytcheson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427462993 PECOS PAC ID: 8022235514 Enrollment ID: I20140806002001 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Cameron Leitch |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1710327077 PECOS PAC ID: 5294952180 Enrollment ID: I20140818001105 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew John Ziegelmann |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1386080018 PECOS PAC ID: 6002057023 Enrollment ID: I20140819000713 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael C Olson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1932549458 PECOS PAC ID: 8527286350 Enrollment ID: I20140820000952 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ryan Youland |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1396181731 PECOS PAC ID: 3870721202 Enrollment ID: I20140820001833 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark A Whealy |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1154767879 PECOS PAC ID: 0941448690 Enrollment ID: I20140821000121 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jessica A Richardson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740692409 PECOS PAC ID: 8224256896 Enrollment ID: I20140822000928 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mustafa M Haddad |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1104269943 PECOS PAC ID: 1456591858 Enrollment ID: I20140826001690 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel A Adamo |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1184967416 PECOS PAC ID: 0648498642 Enrollment ID: I20140905000059 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert A Cates |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1548606114 PECOS PAC ID: 5496993487 Enrollment ID: I20140905000857 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jason T Little |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1366773087 PECOS PAC ID: 6103044029 Enrollment ID: I20140905001193 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel J Scholz |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1386085926 PECOS PAC ID: 9537300033 Enrollment ID: I20140908001295 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Abigail L. Stockham |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1730352550 PECOS PAC ID: 8628205838 Enrollment ID: I20140908001688 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael S Bold |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1003259854 PECOS PAC ID: 2961621875 Enrollment ID: I20140908001855 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Greta Beth Liebo |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1417184326 PECOS PAC ID: 1254550072 Enrollment ID: I20140910000085 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Maria Gonzalez Suarez |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1770878688 PECOS PAC ID: 1355560020 Enrollment ID: I20140910001985 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Diana M Shewmaker |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1245672401 PECOS PAC ID: 9739322744 Enrollment ID: I20140912001912 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Konstantinos Siontis |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1457615999 PECOS PAC ID: 7911143771 Enrollment ID: I20140924002247 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Salwa Bakkali-derksen |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1538446059 PECOS PAC ID: 2769620681 Enrollment ID: I20141006001031 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bryan P Sorensen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1649689829 PECOS PAC ID: 3476773631 Enrollment ID: I20141010000304 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Faye A Otis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174922777 PECOS PAC ID: 7416177555 Enrollment ID: I20141013001289 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shana S Salik |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801211545 PECOS PAC ID: 2264653369 Enrollment ID: I20141014001143 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Yvonne S Butler Tobah |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1437355930 PECOS PAC ID: 7719108794 Enrollment ID: I20141015001819 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Francis I Baffour |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1720427156 PECOS PAC ID: 0042431066 Enrollment ID: I20141016000898 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Trinh N Ho |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1609154848 PECOS PAC ID: 6709049257 Enrollment ID: I20141017000486 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christina M Carney |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760881213 PECOS PAC ID: 2264653195 Enrollment ID: I20141017002232 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Candace L Dalpiaz-seitz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427467190 PECOS PAC ID: 3072734904 Enrollment ID: I20141017002292 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gokhan Anil |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1902928153 PECOS PAC ID: 6305931395 Enrollment ID: I20141027002505 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Padraig P Morris |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1659355659 PECOS PAC ID: 0749341378 Enrollment ID: I20141028002527 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brandon C Voth |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1104228956 PECOS PAC ID: 3870715238 Enrollment ID: I20141119001957 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shayana De Silva |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1033194667 PECOS PAC ID: 5890017065 Enrollment ID: I20141126000158 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shannen R Niemeyer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508270927 PECOS PAC ID: 3072835164 Enrollment ID: I20141126001296 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexander C Egbe |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1104072685 PECOS PAC ID: 3375865405 Enrollment ID: I20141201000876 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kayla A Langhans |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609276542 PECOS PAC ID: 6002138559 Enrollment ID: I20141211001194 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Seth W Gregory |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1891930509 PECOS PAC ID: 1052552817 Enrollment ID: I20141212001332 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew M Thom |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1154660595 PECOS PAC ID: 3870815293 Enrollment ID: I20141212002174 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Edwin Akira Takahashi |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1346683364 PECOS PAC ID: 7517105216 Enrollment ID: I20141224000896 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nathan D Sanders |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1619261708 PECOS PAC ID: 7618292186 Enrollment ID: I20150205000270 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stuart G Trembath |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1083798508 PECOS PAC ID: 0345145215 Enrollment ID: I20150214000040 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Liselle M Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053719237 PECOS PAC ID: 0749505683 Enrollment ID: I20150217000986 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michelle Rene Blankenship |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245579267 PECOS PAC ID: 9234374620 Enrollment ID: I20150427002521 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mary B Donnelly |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841685427 PECOS PAC ID: 9436478831 Enrollment ID: I20150506002982 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Natalie F Mohammad |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750782363 PECOS PAC ID: 8628397783 Enrollment ID: I20150512001808 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Corey P Stump |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1871970855 PECOS PAC ID: 5092035915 Enrollment ID: I20150518000109 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jacob Jentzer |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1538334628 PECOS PAC ID: 2567782261 Enrollment ID: I20150520001985 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Luke E Wood |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1245491588 PECOS PAC ID: 2163609272 Enrollment ID: I20150608002124 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Maryam Mahmood |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1770843989 PECOS PAC ID: 0446561310 Enrollment ID: I20150618001168 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Heidi Jo Gaston |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1649564204 PECOS PAC ID: 1557682911 Enrollment ID: I20150625001997 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian Nils Lundstrom |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1255630182 PECOS PAC ID: 4981916202 Enrollment ID: I20150630000067 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Chad L Hanson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1023216256 PECOS PAC ID: 9133431323 Enrollment ID: I20150630002619 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ajit Goenka |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1578844379 PECOS PAC ID: 4688891989 Enrollment ID: I20150702001839 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Candice A Bookwalter |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1376786798 PECOS PAC ID: 9931322617 Enrollment ID: I20150706001772 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jad Sfeir |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1104189323 PECOS PAC ID: 2062724008 Enrollment ID: I20150706001949 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Awani A Deshmukh |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1104181304 PECOS PAC ID: 7315259991 Enrollment ID: I20150710000519 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian D Proctor |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1932101128 PECOS PAC ID: 8628005238 Enrollment ID: I20150723008587 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lucinda Gruber |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1558777177 PECOS PAC ID: 1355567629 Enrollment ID: I20150723008927 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Benjamin Nordhues |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1336555135 PECOS PAC ID: 4082830666 Enrollment ID: I20150727001377 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gretchen A Zinsli |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700268927 PECOS PAC ID: 0143534784 Enrollment ID: I20150727002793 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Erik Steckler |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1871812065 PECOS PAC ID: 9234443805 Enrollment ID: I20150728003613 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kristin Ann Kinsman |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1386050185 PECOS PAC ID: 6507082740 Enrollment ID: I20150730012575 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Luke C Radel |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1144637182 PECOS PAC ID: 3476771254 Enrollment ID: I20150731014829 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Deborah L Dailey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992101620 PECOS PAC ID: 7113231275 Enrollment ID: I20150803001235 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Barrett Howell |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1487073243 PECOS PAC ID: 6709105091 Enrollment ID: I20150804005424 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sushil Luis |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1447691175 PECOS PAC ID: 4789825480 Enrollment ID: I20150807013911 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ahmad Parvinian |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1992122824 PECOS PAC ID: 6305151440 Enrollment ID: I20150818005251 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Wen-yu V Haines |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1316174410 PECOS PAC ID: 3173838091 Enrollment ID: I20150820010916 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Diego Zaquera Carvalho |
|---|---|
| Provider Type | Practitioner - Sleep Medicine |
| Provider Identifiers | NPI Number: 1366882706 PECOS PAC ID: 9739305954 Enrollment ID: I20150826001325 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Wendaline M Vanburen |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1710306683 PECOS PAC ID: 2567687171 Enrollment ID: I20150901002768 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gabriel G Pokhai |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1922359173 PECOS PAC ID: 9830406685 Enrollment ID: I20150911000741 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Theodora Potretzke |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1154551646 PECOS PAC ID: 4183857139 Enrollment ID: I20150916001181 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy Jo Lee-wiener |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922476324 PECOS PAC ID: 3678880192 Enrollment ID: I20150916001568 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tamara Hartman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770959009 PECOS PAC ID: 6507173903 Enrollment ID: I20150917001332 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michelle M Copley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043695380 PECOS PAC ID: 3779890827 Enrollment ID: I20150922001894 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Colleen M Ireland |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1477921500 PECOS PAC ID: 8123335197 Enrollment ID: I20150923002924 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Renee C Haugsdal |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295102218 PECOS PAC ID: 8820306806 Enrollment ID: I20150925000418 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jessica Stanich |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1033526751 PECOS PAC ID: 1355568056 Enrollment ID: I20151001001667 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ann Braus |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1033401609 PECOS PAC ID: 8628391471 Enrollment ID: I20151022001763 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Scott A Martinson |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1437401775 PECOS PAC ID: 1456660984 Enrollment ID: I20151022001938 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Megan K Wolsey |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1255561304 PECOS PAC ID: 0244549483 Enrollment ID: I20151029000137 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Juliet E Sunberg |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346611811 PECOS PAC ID: 2567762883 Enrollment ID: I20151118001056 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stephanie Burfeind |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184097172 PECOS PAC ID: 0648570721 Enrollment ID: I20151120001769 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | William Thomas Madland |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1487742151 PECOS PAC ID: 6507876893 Enrollment ID: I20151123002930 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James Layne Moore |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1730264037 PECOS PAC ID: 5496772352 Enrollment ID: I20151201002180 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mysoon M Ayuob |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1003251885 PECOS PAC ID: 3476789751 Enrollment ID: I20151221000291 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anthony J Swenson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861866337 PECOS PAC ID: 0547561300 Enrollment ID: I20151221000888 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrew Christian Homb |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1699806265 PECOS PAC ID: 5991821118 Enrollment ID: I20151224000138 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tanya Bredesen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720453137 PECOS PAC ID: 7810298403 Enrollment ID: I20151228001063 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Denise Morcomb |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1184855835 PECOS PAC ID: 7416250501 Enrollment ID: I20160125000007 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Liza Tapia |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780040782 PECOS PAC ID: 8921302720 Enrollment ID: I20160215000814 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ana Casanegra |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1649452020 PECOS PAC ID: 8527256130 Enrollment ID: I20160215001730 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mina Se Hanna |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1205169430 PECOS PAC ID: 0143532457 Enrollment ID: I20160308001957 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Heather J Voigt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295195592 PECOS PAC ID: 3779880505 Enrollment ID: I20160322002518 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Emily P Sander |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1679874515 PECOS PAC ID: 5092012823 Enrollment ID: I20160322002663 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy Marie Stier |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053773499 PECOS PAC ID: 2961709126 Enrollment ID: I20160404000018 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anne E Liwonjo |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1306151675 PECOS PAC ID: 3870724537 Enrollment ID: I20160405002234 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Wen Ma |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1386790517 PECOS PAC ID: 0749368942 Enrollment ID: I20160518001372 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Caitlin A Terpstra |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1902260532 PECOS PAC ID: 7214226976 Enrollment ID: I20160519000473 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Asha Bhatt |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1518258094 PECOS PAC ID: 2264721752 Enrollment ID: I20160524000354 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric Christopher Ehman |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1497045173 PECOS PAC ID: 5698906220 Enrollment ID: I20160601000040 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ashish Khandelwal |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1043565765 PECOS PAC ID: 6406094739 Enrollment ID: I20160603001487 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jason Young |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1285926410 PECOS PAC ID: 0941590764 Enrollment ID: I20160608000113 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Maria De Los Angeles Mendoza De La Garza |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1447699400 PECOS PAC ID: 1254622798 Enrollment ID: I20160614001026 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrew C Schmitt |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1235123902 PECOS PAC ID: 5395781439 Enrollment ID: I20160620000843 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joshua Micah Dorn |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1346683687 PECOS PAC ID: 1759672868 Enrollment ID: I20160621001498 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gustavo Cortes Puentes |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1447694641 PECOS PAC ID: 3779875141 Enrollment ID: I20160705000815 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Milan Khealani |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1952708505 PECOS PAC ID: 8729370051 Enrollment ID: I20160707001015 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nathan Eickstaedt |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1992191894 PECOS PAC ID: 7214220748 Enrollment ID: I20160721000964 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adam R Miller |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1124407010 PECOS PAC ID: 7618289828 Enrollment ID: I20160721001341 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew Ryan Starr |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1972982262 PECOS PAC ID: 9739490418 Enrollment ID: I20160722000471 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Scott Jacob Austin Speelziek |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1962887208 PECOS PAC ID: 0345557674 Enrollment ID: I20160722000857 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ajay A Madhavan |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1285029330 PECOS PAC ID: 1052604402 Enrollment ID: I20160722002269 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Zachary Kelm |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1568841443 PECOS PAC ID: 1254642812 Enrollment ID: I20160725001075 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ian Taylor Mark |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1760860084 PECOS PAC ID: 8628381290 Enrollment ID: I20160725001325 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brendan W Lunn |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1083092266 PECOS PAC ID: 4880987189 Enrollment ID: I20160725001536 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ross Avant |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1801275128 PECOS PAC ID: 7719292275 Enrollment ID: I20160725002147 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kathleen A Young |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1184003089 PECOS PAC ID: 0042521700 Enrollment ID: I20160726000406 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Benjamin J Dewey |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1326425174 PECOS PAC ID: 6204149529 Enrollment ID: I20160726000648 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Garret M Powell |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1962897298 PECOS PAC ID: 5294028478 Enrollment ID: I20160726001069 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ashley V Wong |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1841679347 PECOS PAC ID: 0648582650 Enrollment ID: I20160726001129 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicholas Tan |
|---|---|
| Provider Type | Practitioner - Cardiac Electrophysiology |
| Provider Identifiers | NPI Number: 1770962029 PECOS PAC ID: 0143531806 Enrollment ID: I20160726001701 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Douglas Challener |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1396123709 PECOS PAC ID: 4880915339 Enrollment ID: I20160726002215 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Derick Jones |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1730568759 PECOS PAC ID: 3375854920 Enrollment ID: I20160727002868 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael P Oien |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1356736482 PECOS PAC ID: 1951694744 Enrollment ID: I20160802000384 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alan Michael Sugrue |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1154737690 PECOS PAC ID: 2062638281 Enrollment ID: I20160802000611 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Corrie R Bach |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1023403672 PECOS PAC ID: 7719292093 Enrollment ID: I20160802002472 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gururaj J Kolar |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1619315660 PECOS PAC ID: 9931493657 Enrollment ID: I20160803001487 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brett D Tanning |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1144669755 PECOS PAC ID: 9133445323 Enrollment ID: I20160810001749 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bridget P Pulos |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1003101049 PECOS PAC ID: 4385959766 Enrollment ID: I20160811001450 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brendan M Carr |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1902285331 PECOS PAC ID: 1759698400 Enrollment ID: I20160811001622 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christine E Heintskill |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1578949277 PECOS PAC ID: 4183933633 Enrollment ID: I20160817001823 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stephen Nogel |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1548643315 PECOS PAC ID: 4587959309 Enrollment ID: I20160818000790 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kelsey Kae Schuder |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1982157822 PECOS PAC ID: 9133414501 Enrollment ID: I20160824001281 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Don Codipilly |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1861870289 PECOS PAC ID: 9830400076 Enrollment ID: I20160824002971 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexander Niven |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1578543716 PECOS PAC ID: 2769661826 Enrollment ID: I20160826001684 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Angela I Thoreson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1215482344 PECOS PAC ID: 6406141415 Enrollment ID: I20160829002948 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennie K Knudtson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316490014 PECOS PAC ID: 5294021150 Enrollment ID: I20160901002191 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrea N Moldstad |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487005229 PECOS PAC ID: 5799071551 Enrollment ID: I20160906000897 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew J Buesking |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134672264 PECOS PAC ID: 6406142264 Enrollment ID: I20160906000976 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Megan Griffith |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1962793182 PECOS PAC ID: 9436453404 Enrollment ID: I20160913000077 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lynsi N Romportl |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720533839 PECOS PAC ID: 1951697168 Enrollment ID: I20160913002928 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Usman Anwer |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1316266562 PECOS PAC ID: 7618280066 Enrollment ID: I20160914002774 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alyssa M Larish |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1932588555 PECOS PAC ID: 4183935497 Enrollment ID: I20160920001214 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Chad Dowell |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1790166155 PECOS PAC ID: 8123330107 Enrollment ID: I20160922000416 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Megan H Nelson |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1366680720 PECOS PAC ID: 2769619758 Enrollment ID: I20160922001418 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kelsey S Dowell |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1619358074 PECOS PAC ID: 5092027946 Enrollment ID: I20160923000556 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Cristina Rose Wirtz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306394473 PECOS PAC ID: 8224326491 Enrollment ID: I20161004002463 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Abdulqadir A Ahmad |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1366707556 PECOS PAC ID: 4880984475 Enrollment ID: I20161007001522 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jenna R Hoppenworth |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538511746 PECOS PAC ID: 5193013084 Enrollment ID: I20161010000170 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy S Biondich |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1821226432 PECOS PAC ID: 1254577117 Enrollment ID: I20161018001418 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | William J Remington |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1730183104 PECOS PAC ID: 5698673929 Enrollment ID: I20161025000437 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tarek Z Khalife |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1437388584 PECOS PAC ID: 0143464719 Enrollment ID: I20161102001622 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rebekah Mowers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154877173 PECOS PAC ID: 2264711555 Enrollment ID: I20161109000125 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Breno S Pessanha |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1902812746 PECOS PAC ID: 7416983986 Enrollment ID: I20161208002017 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Vipul A Trivedi |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1457338428 PECOS PAC ID: 0648163824 Enrollment ID: I20161209000020 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy L Mcalister |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316399330 PECOS PAC ID: 2466733878 Enrollment ID: I20161223000101 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian Hendrickson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124567573 PECOS PAC ID: 7315221835 Enrollment ID: I20170301001290 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kyle Elliott |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023478146 PECOS PAC ID: 1951685395 Enrollment ID: I20170301002718 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Laura O'rourke |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740734748 PECOS PAC ID: 5496039596 Enrollment ID: I20170309002531 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Miriam Mowfaq Rassam |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720527088 PECOS PAC ID: 2365727245 Enrollment ID: I20170315001423 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ann W Vaubel |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1235330788 PECOS PAC ID: 5193000511 Enrollment ID: I20170328001207 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kimberly De Paulo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417308701 PECOS PAC ID: 6103107990 Enrollment ID: I20170329001973 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ratnasari Padang |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1548642077 PECOS PAC ID: 2668784398 Enrollment ID: I20170420000535 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Betzalel Reich |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1336460344 PECOS PAC ID: 1254571078 Enrollment ID: I20170508002028 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kara Dupuy-mccauley |
|---|---|
| Provider Type | Practitioner - Sleep Medicine |
| Provider Identifiers | NPI Number: 1932514031 PECOS PAC ID: 6800173402 Enrollment ID: I20170509001804 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Madiha Fida |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1205241676 PECOS PAC ID: 4183920697 Enrollment ID: I20170519000861 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paul D Williams |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1316365281 PECOS PAC ID: 8123320926 Enrollment ID: I20170522002897 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kari A Felten Mylenbusch |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1003132465 PECOS PAC ID: 3870786007 Enrollment ID: I20170524002025 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alisha Morgan |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1053546937 PECOS PAC ID: 2466698048 Enrollment ID: I20170601000981 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dong Kun Kim |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1265789457 PECOS PAC ID: 7719254390 Enrollment ID: I20170602000633 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Meagan C Uzee |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1124386404 PECOS PAC ID: 0749575835 Enrollment ID: I20170606001502 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Allan M Bates |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1285041640 PECOS PAC ID: 0840411278 Enrollment ID: I20170607001770 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Patricia Ann Fenstermacher |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043626047 PECOS PAC ID: 8426275884 Enrollment ID: I20170608000807 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jason H Planas |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1497175772 PECOS PAC ID: 6608174289 Enrollment ID: I20170608001303 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Don Stott |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1275821449 PECOS PAC ID: 2769787829 Enrollment ID: I20170612002973 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel E Sanchez Pellecer |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1386042885 PECOS PAC ID: 3971871922 Enrollment ID: I20170614002716 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicholas Gregg |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1528401296 PECOS PAC ID: 2466758354 Enrollment ID: I20170615001637 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Regina Maria Mackey |
|---|---|
| Provider Type | Practitioner - Hospice/palliative Care |
| Provider Identifiers | NPI Number: 1710320411 PECOS PAC ID: 7214234772 Enrollment ID: I20170621002946 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rachel M Ziegler |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1083906150 PECOS PAC ID: 5597066720 Enrollment ID: I20170628001188 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Melanie Gentry |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1700868999 PECOS PAC ID: 7315973633 Enrollment ID: I20170629002804 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kanika Khandelwal |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1457768889 PECOS PAC ID: 9133499775 Enrollment ID: I20170714001159 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lydia Ng |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1174879076 PECOS PAC ID: 9537439393 Enrollment ID: I20170727000133 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kevin Chodnicki |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1962866632 PECOS PAC ID: 2466744974 Enrollment ID: I20170801000292 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Aaron Bradley Klassen |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1750745428 PECOS PAC ID: 9638461163 Enrollment ID: I20170801000571 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David Bartlett |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1508216409 PECOS PAC ID: 2961794730 Enrollment ID: I20170801002010 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Talha Niaz |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1235513284 PECOS PAC ID: 4587971627 Enrollment ID: I20170801002116 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel Jordan Stephens |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1144464223 PECOS PAC ID: 2961706726 Enrollment ID: I20170802000954 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michelle Beth Herberts |
|---|---|
| Provider Type | Practitioner - Sleep Medicine |
| Provider Identifiers | NPI Number: 1003270786 PECOS PAC ID: 6204128218 Enrollment ID: I20170808002629 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeffrey Huang |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1295199883 PECOS PAC ID: 3779875075 Enrollment ID: I20170809004199 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Craig F Tschautscher |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1316301096 PECOS PAC ID: 6507158227 Enrollment ID: I20170814000764 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alicia Grace Floyd |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1033408505 PECOS PAC ID: 2567680713 Enrollment ID: I20170814001669 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rajasekhar R Madathala |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1932477536 PECOS PAC ID: 6901021583 Enrollment ID: I20170814002031 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Vamshi Mugu |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1215391842 PECOS PAC ID: 8527350693 Enrollment ID: I20170814003330 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Marcella Kaddoura |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1750745220 PECOS PAC ID: 5193018356 Enrollment ID: I20170815002364 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexander Finch |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1326402900 PECOS PAC ID: 7810289121 Enrollment ID: I20170815002600 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Heather Talley |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1245694637 PECOS PAC ID: 7315230083 Enrollment ID: I20170815004437 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sebastian Baker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902326994 PECOS PAC ID: 2466725221 Enrollment ID: I20170830002664 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eeeln Buckarma |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1932541133 PECOS PAC ID: 0042502080 Enrollment ID: I20170901002391 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian Burkett |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1811344740 PECOS PAC ID: 7517230857 Enrollment ID: I20170907001933 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katie E Hinderaker |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1548615255 PECOS PAC ID: 8426340183 Enrollment ID: I20170907002794 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hossam M Alzu'bi |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1821403783 PECOS PAC ID: 7012136534 Enrollment ID: I20170913000298 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Timothy Jaykel |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1265895551 PECOS PAC ID: 1254623499 Enrollment ID: I20170913002645 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ivana Ho |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1952765620 PECOS PAC ID: 7618269184 Enrollment ID: I20170914003238 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stephanie K Meyer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306367578 PECOS PAC ID: 3173897147 Enrollment ID: I20170914004039 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Saba Rahman |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1043465586 PECOS PAC ID: 4688822273 Enrollment ID: I20170915002609 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Patti A Paris |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1336100494 PECOS PAC ID: 2769373430 Enrollment ID: I20170927000167 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian L Wariboko |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1457779563 PECOS PAC ID: 8325267420 Enrollment ID: I20171006000257 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Melinda L Wiese |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801313796 PECOS PAC ID: 8224303755 Enrollment ID: I20171009001824 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Douglas Sommers |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1699204917 PECOS PAC ID: 9234404708 Enrollment ID: I20171010000085 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexander Neal Kurjatko |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1811277890 PECOS PAC ID: 2264708866 Enrollment ID: I20171026001894 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tristan N Covington |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1124482765 PECOS PAC ID: 2466740774 Enrollment ID: I20171031000045 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Regan Theiler |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1609069558 PECOS PAC ID: 9335232230 Enrollment ID: I20171107000242 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jordan Buendorf |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740700285 PECOS PAC ID: 0941566756 Enrollment ID: I20171110002526 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ryan Jean Baptiste |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1497997050 PECOS PAC ID: 4587789326 Enrollment ID: I20171113001423 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Maria A Farmer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427204577 PECOS PAC ID: 5597820845 Enrollment ID: I20171113001600 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paul Raymond Horvath |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1912029141 PECOS PAC ID: 8527169481 Enrollment ID: I20171113001725 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark Christian Bildsoe |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1912978529 PECOS PAC ID: 2567458458 Enrollment ID: I20171113002070 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gregory Brickner |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1720059330 PECOS PAC ID: 0941296834 Enrollment ID: I20171116000396 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David R. Dare |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1659710291 PECOS PAC ID: 8022375443 Enrollment ID: I20171120002061 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrew K Brevik |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1376513903 PECOS PAC ID: 7911035738 Enrollment ID: I20171129001601 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Susan Marie Cullinan |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1215995980 PECOS PAC ID: 7315040284 Enrollment ID: I20171129003514 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joshua M Baruth |
|---|---|
| Provider Type | Practitioner - Geriatric Psychiatry |
| Provider Identifiers | NPI Number: 1588028161 PECOS PAC ID: 1951693183 Enrollment ID: I20171211000652 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Scott Jeffrey Cole |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1124099551 PECOS PAC ID: 6608845177 Enrollment ID: I20171218000353 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gregory A Taylor |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1326564121 PECOS PAC ID: 4183982242 Enrollment ID: I20171218003133 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David J Rea |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1245218692 PECOS PAC ID: 8921150665 Enrollment ID: I20171229002076 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas Francis Murphy |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1811973613 PECOS PAC ID: 7719943281 Enrollment ID: I20180104000851 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tam Nguyen Tran |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760906010 PECOS PAC ID: 4587923800 Enrollment ID: I20180112001132 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Aditya S Shah |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1740697598 PECOS PAC ID: 2567772643 Enrollment ID: I20180118000962 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Susan Lea Andersen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689188351 PECOS PAC ID: 0345509253 Enrollment ID: I20180123001995 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kathryn Louise Poppe |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1154835098 PECOS PAC ID: 7618237793 Enrollment ID: I20180209001829 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jay P Heiken |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1942392444 PECOS PAC ID: 8729127188 Enrollment ID: I20180215000537 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ana Dahl |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1639683691 PECOS PAC ID: 5496016545 Enrollment ID: I20180306001250 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ashley A Anderson |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1063707461 PECOS PAC ID: 7719106087 Enrollment ID: I20180314001930 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John C Benson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1134462963 PECOS PAC ID: 8426353541 Enrollment ID: I20180531002876 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Petrice Mostardi Cogswell |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1487997557 PECOS PAC ID: 4385947894 Enrollment ID: I20180606001437 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Veronica E Radigan |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1740643105 PECOS PAC ID: 2264724715 Enrollment ID: I20180611001459 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Richard G Frimpong |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1619310612 PECOS PAC ID: 0244458768 Enrollment ID: I20180614002492 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrew Zenhong Chow |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1700178159 PECOS PAC ID: 1456646314 Enrollment ID: I20180614002946 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sophia Pillai |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1194910257 PECOS PAC ID: 7012157290 Enrollment ID: I20180615000997 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Steven A Messina |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1477642536 PECOS PAC ID: 5597920132 Enrollment ID: I20180619002550 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dhauna Prasad Prasad Karam Chandra Mohan Prasad |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1265810923 PECOS PAC ID: 1254686686 Enrollment ID: I20180626001249 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Haixia Qin |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1952697286 PECOS PAC ID: 7719108265 Enrollment ID: I20180702000021 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hanyin Wang |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1174905939 PECOS PAC ID: 9739478322 Enrollment ID: I20180709003077 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kjersten A Nett |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1023503711 PECOS PAC ID: 7517214596 Enrollment ID: I20180723000720 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Vivek Prasad |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1760692032 PECOS PAC ID: 2769675701 Enrollment ID: I20180726002381 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sadik Abdikadir Ali |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1811377229 PECOS PAC ID: 6305193996 Enrollment ID: I20180730000213 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Peter J. Moore |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1528599917 PECOS PAC ID: 8325310907 Enrollment ID: I20180731002504 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nam Ju Lee |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1659688679 PECOS PAC ID: 2567697345 Enrollment ID: I20180731002844 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Zhenmei Zhang |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1811428121 PECOS PAC ID: 0042582645 Enrollment ID: I20180801001785 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adam Sharp Cole |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1285999557 PECOS PAC ID: 3971735226 Enrollment ID: I20180802000478 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Benjamin Satterfield |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1083147128 PECOS PAC ID: 0941572515 Enrollment ID: I20180802001633 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | William Gus Breen |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1437683562 PECOS PAC ID: 3476801697 Enrollment ID: I20180804000030 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric Ryan Pease |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1922539634 PECOS PAC ID: 3779855291 Enrollment ID: I20180806002731 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ryan Michael Finn |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1558898684 PECOS PAC ID: 7810269008 Enrollment ID: I20180806003180 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Donnie Keith Starnes |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1376987826 PECOS PAC ID: 8921226416 Enrollment ID: I20180807002583 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nathaniel Joseph Lombardi |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1801247580 PECOS PAC ID: 2668720533 Enrollment ID: I20180809000075 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mohamad Adada |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1528590734 PECOS PAC ID: 3678843620 Enrollment ID: I20180809005876 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anousheh Shafa |
|---|---|
| Provider Type | Practitioner - Gynecological Oncology |
| Provider Identifiers | NPI Number: 1225563836 PECOS PAC ID: 9739453697 Enrollment ID: I20180814001612 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Benjamin W Iliff |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1114317955 PECOS PAC ID: 1759653322 Enrollment ID: I20180814001714 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah J Chalmers |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1740612241 PECOS PAC ID: 8426379355 Enrollment ID: I20180815000258 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark Watson |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1043263247 PECOS PAC ID: 2264488477 Enrollment ID: I20180817001607 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Fareeda Taher Nazer Hussain |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1396181483 PECOS PAC ID: 1951604818 Enrollment ID: I20180823000195 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Marla Kay Halliday |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902392707 PECOS PAC ID: 6406105204 Enrollment ID: I20180827002621 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicholas C Canzanello |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1356879654 PECOS PAC ID: 8729351549 Enrollment ID: I20180828001441 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Janice Malay |
|---|---|
| Provider Type | Practitioner - Neuropsychiatry |
| Provider Identifiers | NPI Number: 1861845018 PECOS PAC ID: 4385918242 Enrollment ID: I20180828001757 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Angela Lynn Chisholm |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710473301 PECOS PAC ID: 2062762636 Enrollment ID: I20180830003024 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Melissa Kay Hart |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1255570636 PECOS PAC ID: 8022250067 Enrollment ID: I20180906000106 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ion S Chuang |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1821034448 PECOS PAC ID: 2860488319 Enrollment ID: I20180906000817 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dayne Henry Voelker |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1578096855 PECOS PAC ID: 2466724943 Enrollment ID: I20180907000053 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Emily Jo Catalano |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1952833378 PECOS PAC ID: 5092087692 Enrollment ID: I20180910001659 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Scott A Martin |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1073590956 PECOS PAC ID: 3173528494 Enrollment ID: I20180911001564 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Melanie Jane Devries |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467938860 PECOS PAC ID: 9830449826 Enrollment ID: I20180912003727 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kyle Mark Levi Unsdorfer |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1285165183 PECOS PAC ID: 1557633930 Enrollment ID: I20180914001110 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah Baumgarten |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1255861035 PECOS PAC ID: 1456624709 Enrollment ID: I20180925001292 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark E. Deyo-svendsen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1124077839 PECOS PAC ID: 3870538242 Enrollment ID: I20180926000694 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Justin C Boeke |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1073933321 PECOS PAC ID: 7012212384 Enrollment ID: I20180927001976 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeremy Douglas Collins |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1922121243 PECOS PAC ID: 1850569104 Enrollment ID: I20181001000473 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel Chiang |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1336676279 PECOS PAC ID: 6103198627 Enrollment ID: I20181002000517 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Fahad Faruqi |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1710367008 PECOS PAC ID: 1052623550 Enrollment ID: I20181002002262 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kathryn Ann Robinson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1780600254 PECOS PAC ID: 9537163274 Enrollment ID: I20181009003533 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mairead Bartley |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1255718482 PECOS PAC ID: 8224358692 Enrollment ID: I20181024001071 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hari Prasad Reddy Korsapati |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1639563265 PECOS PAC ID: 2264785435 Enrollment ID: I20181106000499 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher Ray Lee |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174006563 PECOS PAC ID: 2466705645 Enrollment ID: I20181106000853 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Erica Lynn-eischen Bauhs |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1629544770 PECOS PAC ID: 8921352048 Enrollment ID: I20181108000546 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Melissa Johnson Bertelson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1932675352 PECOS PAC ID: 8123362712 Enrollment ID: I20181210000242 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrea Lynn Engdahl |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1427531326 PECOS PAC ID: 6204170673 Enrollment ID: I20181212001175 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gina Ann Suh |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1609075977 PECOS PAC ID: 4789778507 Enrollment ID: I20181228000016 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katie Machacek |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912477084 PECOS PAC ID: 4486991031 Enrollment ID: I20190122000116 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Victoria M Silvera |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1467539908 PECOS PAC ID: 7911966916 Enrollment ID: I20190201001908 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer Rivers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861962045 PECOS PAC ID: 9335487057 Enrollment ID: I20190205001263 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ashraf Adel Samy Gerges |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1003874264 PECOS PAC ID: 1355326943 Enrollment ID: I20190208002232 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lance W. Weagant |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1881671790 PECOS PAC ID: 7012937550 Enrollment ID: I20190225002470 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mallory Lynn Berry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356814271 PECOS PAC ID: 4880933456 Enrollment ID: I20190226000277 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lee Joseph Bakewell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1669936480 PECOS PAC ID: 7719226315 Enrollment ID: I20190226001483 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Megan Herbers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912470857 PECOS PAC ID: 9335488949 Enrollment ID: I20190226002155 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David Rushlow |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1790775294 PECOS PAC ID: 8022051408 Enrollment ID: I20190301000280 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Heather Larson |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1306319512 PECOS PAC ID: 9335488667 Enrollment ID: I20190305001221 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Colin Bucks |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1962441741 PECOS PAC ID: 9335142165 Enrollment ID: I20190315001055 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paschalis Vergidis |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1780858613 PECOS PAC ID: 0547315442 Enrollment ID: I20190315001818 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Colin Patterson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1992049597 PECOS PAC ID: 9739429465 Enrollment ID: I20190315002475 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mariah G Kelly |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1194282541 PECOS PAC ID: 0941540942 Enrollment ID: I20190328001078 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lisa Mccabe Evans |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487118345 PECOS PAC ID: 9234470410 Enrollment ID: I20190417000022 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Meagan E Vlasek |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790239952 PECOS PAC ID: 1850686080 Enrollment ID: I20190502002093 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Heather Miller |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336703479 PECOS PAC ID: 0749523405 Enrollment ID: I20190521000361 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James Michael Bisanti |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1063850980 PECOS PAC ID: 4688818297 Enrollment ID: I20190523000371 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Seng Yue Joshua Foong |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1922453133 PECOS PAC ID: 8628313053 Enrollment ID: I20190524000271 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Darya P Shlapak |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1760892624 PECOS PAC ID: 9335420496 Enrollment ID: I20190604002997 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Avinash Nehra |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1952780199 PECOS PAC ID: 8628389368 Enrollment ID: I20190612000983 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mohamed Yousuf Warsame |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1962865527 PECOS PAC ID: 3678865482 Enrollment ID: I20190612001489 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John A Halerz |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1114375532 PECOS PAC ID: 0648562439 Enrollment ID: I20190619001884 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Narayan Gurukrip Kowlgi |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1891044400 PECOS PAC ID: 4880913102 Enrollment ID: I20190625000980 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shaina Rae Watson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154883346 PECOS PAC ID: 9638403611 Enrollment ID: I20190625001957 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Trisha Osheim |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1477747053 PECOS PAC ID: 9931433836 Enrollment ID: I20190626003229 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ali Ahmad |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1881145647 PECOS PAC ID: 1254619075 Enrollment ID: I20190701001490 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Erin N Kastl |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1023469806 PECOS PAC ID: 0345534962 Enrollment ID: I20190705000290 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Karun Badwal |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1003268483 PECOS PAC ID: 1759660293 Enrollment ID: I20190709001492 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew Patrick Thorpe |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1215372081 PECOS PAC ID: 2567797384 Enrollment ID: I20190716000802 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Francis Owusu |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841771532 PECOS PAC ID: 1557697059 Enrollment ID: I20190722001365 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Philip Zorn |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1447600556 PECOS PAC ID: 0345534178 Enrollment ID: I20190722001396 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sara Ann Schroeder Hevesi |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1013368414 PECOS PAC ID: 6709173727 Enrollment ID: I20190723000714 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Leah M Lindbeck |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497316830 PECOS PAC ID: 9931435120 Enrollment ID: I20190725001887 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Syed Haris Ali |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1033598214 PECOS PAC ID: 7416283932 Enrollment ID: I20190729000144 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stephanie Y Torres |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1336645126 PECOS PAC ID: 6406104363 Enrollment ID: I20190730000934 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexander Kellington Bratt |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1265876445 PECOS PAC ID: 2961767181 Enrollment ID: I20190730002779 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert Kerwin Strother |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1518463595 PECOS PAC ID: 1456608462 Enrollment ID: I20190730002862 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nathan Seven |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1003307075 PECOS PAC ID: 6608126925 Enrollment ID: I20190731001072 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel Burczak |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1245735703 PECOS PAC ID: 6507113560 Enrollment ID: I20190731004162 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah Lund |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1700381456 PECOS PAC ID: 0749537751 Enrollment ID: I20190801000229 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Livia Maria Frota Lima |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1215460415 PECOS PAC ID: 8224386057 Enrollment ID: I20190801000594 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Harrison John Gerdes |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1518462209 PECOS PAC ID: 9335496256 Enrollment ID: I20190801000595 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Benjamin Krippendorf |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1487159521 PECOS PAC ID: 7618225624 Enrollment ID: I20190802000672 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Won S Song |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1144201930 PECOS PAC ID: 4183796204 Enrollment ID: I20190805000698 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexander David Ritchie Ginsburg |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1780180653 PECOS PAC ID: 2769739804 Enrollment ID: I20190805001367 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Derek Opp |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1366947012 PECOS PAC ID: 1456608090 Enrollment ID: I20190806002043 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael D'netto |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1538666839 PECOS PAC ID: 8022365824 Enrollment ID: I20190807000035 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anthony Kashou |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1629572557 PECOS PAC ID: 5799032769 Enrollment ID: I20190807000059 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel Montville |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1952806093 PECOS PAC ID: 9830446756 Enrollment ID: I20190807000464 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Allyson Palmer |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1447755707 PECOS PAC ID: 4880941715 Enrollment ID: I20190807002115 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jaime Lynn Reigel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275005548 PECOS PAC ID: 6800123985 Enrollment ID: I20190813000190 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Patrick Navin |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1427570852 PECOS PAC ID: 8426320797 Enrollment ID: I20190813001501 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeffrey W Wilder |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1164490611 PECOS PAC ID: 8224010905 Enrollment ID: I20190813003178 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert J Fagnant |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1093734360 PECOS PAC ID: 4385534346 Enrollment ID: I20190814003928 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bryan Joseph Neth |
|---|---|
| Provider Type | Practitioner - Neuropsychiatry |
| Provider Identifiers | NPI Number: 1093210775 PECOS PAC ID: 1759639586 Enrollment ID: I20190816001534 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gordon J Ruan |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1982109369 PECOS PAC ID: 8426305491 Enrollment ID: I20190822000838 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Winny Kerubo Omwamba |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508425828 PECOS PAC ID: 4385972538 Enrollment ID: I20190826002368 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sandy Kay Clayton |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1578827465 PECOS PAC ID: 4082852751 Enrollment ID: I20190827000167 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Laurie J Johnson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1083649339 PECOS PAC ID: 7517295611 Enrollment ID: I20190828000720 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Angela Eb Lawrence |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1942552534 PECOS PAC ID: 1759619851 Enrollment ID: I20190828000896 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carol Susan Gardner |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1245259746 PECOS PAC ID: 3375871395 Enrollment ID: I20190828002447 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Taylor Jon Helmus |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1609120179 PECOS PAC ID: 3870822794 Enrollment ID: I20190831000273 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah Lynne Gerard |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518513639 PECOS PAC ID: 1355670027 Enrollment ID: I20190905000129 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kerry A Finne |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1184659633 PECOS PAC ID: 8527397223 Enrollment ID: I20190905001519 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Emily Jean Flaaen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1891726055 PECOS PAC ID: 1355670092 Enrollment ID: I20190905003372 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Courtney A Streit |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487689741 PECOS PAC ID: 4880923531 Enrollment ID: I20190905003519 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Affan Irfan |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1942588066 PECOS PAC ID: 4789958893 Enrollment ID: I20190909003725 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy Lynn Heins |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659925246 PECOS PAC ID: 0547599862 Enrollment ID: I20190912000965 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Prabhakar Rajiah |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1033230701 PECOS PAC ID: 2961509427 Enrollment ID: I20190912003030 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Elizabeth Ojukwu |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1295182772 PECOS PAC ID: 0941550651 Enrollment ID: I20190926000438 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jill Depke |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275631558 PECOS PAC ID: 6608895594 Enrollment ID: I20190930003115 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Aliza Faigel Weinman |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1578683165 PECOS PAC ID: 8820184286 Enrollment ID: I20191008000722 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Yasmeen Tandon |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1992021067 PECOS PAC ID: 3476796327 Enrollment ID: I20191014003281 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David M Phelan |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1679646715 PECOS PAC ID: 3274585013 Enrollment ID: I20191015001825 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Melanie Kay Busch |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1366091266 PECOS PAC ID: 1254662596 Enrollment ID: I20191017000646 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adedayo Temitope Dosumu |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174019038 PECOS PAC ID: 3870824139 Enrollment ID: I20191017001572 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kelly J Vold |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962634428 PECOS PAC ID: 6305983008 Enrollment ID: I20191017002882 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christine Sachs |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1144573973 PECOS PAC ID: 5193057842 Enrollment ID: I20191029003055 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Aicha Sylvie Katty |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457909384 PECOS PAC ID: 3971835679 Enrollment ID: I20191030001251 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jasmine Kamboj |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1144557638 PECOS PAC ID: 8820380272 Enrollment ID: I20191105001066 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bailey Breanne Staffan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508415522 PECOS PAC ID: 3577995612 Enrollment ID: I20191112001164 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anna C Tipton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063056935 PECOS PAC ID: 1254763279 Enrollment ID: I20191113001936 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sadia Munawar |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1447649017 PECOS PAC ID: 9335452713 Enrollment ID: I20191120001364 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Moses Kubwimana Mhayamaguru |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1417397811 PECOS PAC ID: 3173818473 Enrollment ID: I20191126003122 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mary E Verdun |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417593922 PECOS PAC ID: 2163855495 Enrollment ID: I20191127001241 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eukeria Tanyir Boila Epse Nsameluh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477191807 PECOS PAC ID: 5294160420 Enrollment ID: I20200116002308 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Leslie Carranza |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1770697971 PECOS PAC ID: 1456475144 Enrollment ID: I20200121002524 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adekunle Odubeko |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1588200968 PECOS PAC ID: 9032545538 Enrollment ID: I20200131001198 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher W Saenz |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1376174672 PECOS PAC ID: 1355777111 Enrollment ID: I20200214001381 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michelle Genevieive Rogers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1437799319 PECOS PAC ID: 2860829090 Enrollment ID: I20200227000847 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Faro Saya Jones |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1740626142 PECOS PAC ID: 2769819986 Enrollment ID: I20200228001660 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew E Cabrera Svendsen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1710373337 PECOS PAC ID: 1658687397 Enrollment ID: I20200309001357 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jacqueline J Meyer-rostad |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942832712 PECOS PAC ID: 3870921687 Enrollment ID: I20200310000475 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joseph F Gonzales |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1326679853 PECOS PAC ID: 8921436692 Enrollment ID: I20200311000609 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shelby Rae Spandl |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1528327160 PECOS PAC ID: 0648600056 Enrollment ID: I20200428000114 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark T Lee |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1245625003 PECOS PAC ID: 9739484874 Enrollment ID: I20200502000009 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sydney Mcinnis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871138263 PECOS PAC ID: 2062843287 Enrollment ID: I20200504000112 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Supavit Chesdachai |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1982138228 PECOS PAC ID: 6800161456 Enrollment ID: I20200520001659 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kristina T Flicek |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1568872364 PECOS PAC ID: 1456678986 Enrollment ID: I20200523000033 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adjoa Denyo Zakhia |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1093096471 PECOS PAC ID: 4880826346 Enrollment ID: I20200526001847 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Miriam E Levi |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1538432323 PECOS PAC ID: 3476797838 Enrollment ID: I20200527002446 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Akeem Ronell Lewis |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1760833941 PECOS PAC ID: 9931442688 Enrollment ID: I20200528000857 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jidi Gao |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1710364906 PECOS PAC ID: 1759677529 Enrollment ID: I20200602000571 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joe D Starke |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1053315879 PECOS PAC ID: 8224057484 Enrollment ID: I20200605001674 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dawn M Snow |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1093711566 PECOS PAC ID: 2860413101 Enrollment ID: I20200608000503 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Victor Nettey |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1528417037 PECOS PAC ID: 5092137091 Enrollment ID: I20200620000077 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher Jean-pierre Francois |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1902938467 PECOS PAC ID: 7315048139 Enrollment ID: I20200622002710 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sanskriti Mishra |
|---|---|
| Provider Type | Practitioner - Neuropsychiatry |
| Provider Identifiers | NPI Number: 1790205300 PECOS PAC ID: 1153697099 Enrollment ID: I20200625002933 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Josef Pleticha |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1124400593 PECOS PAC ID: 6103118278 Enrollment ID: I20200627000030 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gina K Lee |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1174147607 PECOS PAC ID: 2264854827 Enrollment ID: I20200629000017 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Wigdan Hassan Eltayeb Farah |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1043741655 PECOS PAC ID: 7517230311 Enrollment ID: I20200629001106 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tuoyo Mene-afejuku |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1184076853 PECOS PAC ID: 3072848209 Enrollment ID: I20200630002627 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ray Qian |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1285051565 PECOS PAC ID: 3072732460 Enrollment ID: I20200716000272 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kyaw Zaw Hein |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1861913907 PECOS PAC ID: 5698045052 Enrollment ID: I20200721002914 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher Anh-thao Dinh |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1285294389 PECOS PAC ID: 4082949581 Enrollment ID: I20200723001055 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sara T Medina-bielski |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1033679170 PECOS PAC ID: 1254665201 Enrollment ID: I20200730000067 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Justin Schappell |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1750842464 PECOS PAC ID: 9234554858 Enrollment ID: I20200730000076 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark W Kaczor |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1497319065 PECOS PAC ID: 1759616006 Enrollment ID: I20200803001868 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Aurora S H Peck Norman |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1053976514 PECOS PAC ID: 7113251620 Enrollment ID: I20200804001574 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hadiyah Yasin Ahmad |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1497216394 PECOS PAC ID: 9537493382 Enrollment ID: I20200811000073 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mackenzie Leigh Haller |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578977450 PECOS PAC ID: 4587080338 Enrollment ID: I20200811003397 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Patrick J Bigaouette |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1962851394 PECOS PAC ID: 8224375605 Enrollment ID: I20200812003450 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Emily Anggelis Hines |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1427519685 PECOS PAC ID: 6305189515 Enrollment ID: I20200813000923 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Samuel Isaias Garcia |
|---|---|
| Provider Type | Practitioner - Critical Care (intensivists) |
| Provider Identifiers | NPI Number: 1265993000 PECOS PAC ID: 4587990288 Enrollment ID: I20200813001019 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Liyanage A M Perera |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1821441163 PECOS PAC ID: 1254669856 Enrollment ID: I20200813001958 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rolando Daniel Calderon |
|---|---|
| Provider Type | Practitioner - Cardiac Surgery |
| Provider Identifiers | NPI Number: 1528528528 PECOS PAC ID: 1658606181 Enrollment ID: I20200818002994 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Saam Dilmaghani |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1477014306 PECOS PAC ID: 4486988037 Enrollment ID: I20200820002979 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ezzaddin Al Wahsh |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1033525456 PECOS PAC ID: 6507156981 Enrollment ID: I20200821000056 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer Jane Gile |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1336609288 PECOS PAC ID: 6608101191 Enrollment ID: I20200821002818 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kristin E Karim |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1811309131 PECOS PAC ID: 8224255526 Enrollment ID: I20200824001690 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kelley Nicole Dages |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1508326695 PECOS PAC ID: 9739413238 Enrollment ID: I20200824002293 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ross Ashe Barman |
|---|---|
| Provider Type | Practitioner - Pain Management |
| Provider Identifiers | NPI Number: 1508326133 PECOS PAC ID: 2365777836 Enrollment ID: I20200825002931 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kishor Joshi |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1770005225 PECOS PAC ID: 2062839590 Enrollment ID: I20200829000033 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mohamed A Hassan |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1578091690 PECOS PAC ID: 9335413749 Enrollment ID: I20200904000068 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian Jacob Johnson |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1689134710 PECOS PAC ID: 4183959547 Enrollment ID: I20200912000070 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael Cole |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1518300870 PECOS PAC ID: 1052638608 Enrollment ID: I20200914000766 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarayna Mcguire |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1972063154 PECOS PAC ID: 9537493168 Enrollment ID: I20200915000139 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nadia Akhiyat |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1922664507 PECOS PAC ID: 7911232418 Enrollment ID: I20200916000106 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carrie A Wojick |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1023545829 PECOS PAC ID: 1557789062 Enrollment ID: I20200916000111 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jack William Mc Hugh |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1639731961 PECOS PAC ID: 1254666811 Enrollment ID: I20200921002631 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mason James Webb |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1306306600 PECOS PAC ID: 6709111065 Enrollment ID: I20200922000604 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mark David Rollins |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1750330064 PECOS PAC ID: 3779569637 Enrollment ID: I20200922001407 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Oluwafunmilayo O Oyatogun |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1932550415 PECOS PAC ID: 3173817939 Enrollment ID: I20200924000777 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexander Covington |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1730422429 PECOS PAC ID: 8820335896 Enrollment ID: I20201001000071 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mauro Schenone |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1750588596 PECOS PAC ID: 5092854000 Enrollment ID: I20201001000871 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexander Scott Hines |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1285195800 PECOS PAC ID: 6305171877 Enrollment ID: I20201001003464 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joseph Daniel Blessman |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1396206280 PECOS PAC ID: 0749514313 Enrollment ID: I20201006000685 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kelly Horst |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1134383748 PECOS PAC ID: 9537318068 Enrollment ID: I20201008001888 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jessica K Phelps |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275146680 PECOS PAC ID: 7113347519 Enrollment ID: I20201026000004 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeffrey Michael Post |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659985281 PECOS PAC ID: 4385064666 Enrollment ID: I20201027000775 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Scott Michael Canepa |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1184185704 PECOS PAC ID: 9638403181 Enrollment ID: I20201027001392 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Guleid Hussein |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1669993739 PECOS PAC ID: 7214207869 Enrollment ID: I20201104000997 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jose James |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1932662749 PECOS PAC ID: 0547594095 Enrollment ID: I20201105000379 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Megan Thompson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1033736624 PECOS PAC ID: 1456763770 Enrollment ID: I20201210001028 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ralph Thomas Perry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225659246 PECOS PAC ID: 6901218247 Enrollment ID: I20201210001986 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Julie Rossi Polonczyk |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1831450527 PECOS PAC ID: 9931434032 Enrollment ID: I20201230001955 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kristen Rae Petterson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427652908 PECOS PAC ID: 2062825490 Enrollment ID: I20210104001697 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tammy Lynn Perttula |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720689920 PECOS PAC ID: 0143634766 Enrollment ID: I20210122000319 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lisa J Wimmer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134715477 PECOS PAC ID: 4486069903 Enrollment ID: I20210216000912 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Peter Andrew Lowry |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1316108731 PECOS PAC ID: 3971746520 Enrollment ID: I20210219002471 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Summer Nicole Perry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255922928 PECOS PAC ID: 5597171850 Enrollment ID: I20210311000026 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kayla Terese Patterson |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1417545963 PECOS PAC ID: 8820404072 Enrollment ID: I20210312000603 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shannon M Dahle |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598342552 PECOS PAC ID: 3678981404 Enrollment ID: I20210416000084 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John V Thomas |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1790871796 PECOS PAC ID: 8921155045 Enrollment ID: I20210427001322 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Maureen Patricia Swanson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831777333 PECOS PAC ID: 5698184992 Enrollment ID: I20210517000575 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Abigail M Wacholz |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1972186658 PECOS PAC ID: 4587073820 Enrollment ID: I20210517002441 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bolun Liu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1861988511 PECOS PAC ID: 0547514473 Enrollment ID: I20210518000328 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Qiping Xu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1245726686 PECOS PAC ID: 5395095392 Enrollment ID: I20210518001430 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Caleb Mawulikofi Tsetse |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1285013813 PECOS PAC ID: 7315284924 Enrollment ID: I20210526001126 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Moldovan Sabov |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1912403403 PECOS PAC ID: 8527467166 Enrollment ID: I20210601002238 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stacy L Stratmann Egan |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1760400733 PECOS PAC ID: 8426018573 Enrollment ID: I20210604000009 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Xia Zhou |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1871099515 PECOS PAC ID: 3375891872 Enrollment ID: I20210604000101 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sumeet K Yadav |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1508358656 PECOS PAC ID: 6103166707 Enrollment ID: I20210607001075 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Abdul Wahab |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1649622242 PECOS PAC ID: 8426344730 Enrollment ID: I20210607002662 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Geoffrey D Huntley |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1962905760 PECOS PAC ID: 2264832492 Enrollment ID: I20210610000024 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paul J Farnsworth |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1407207236 PECOS PAC ID: 1153721311 Enrollment ID: I20210610000980 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer Ann Braaten |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1780258715 PECOS PAC ID: 2062812811 Enrollment ID: I20210615003339 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Vikas Le-kumar |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1487159000 PECOS PAC ID: 7315291606 Enrollment ID: I20210618000883 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Akriti Khanna |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1669883062 PECOS PAC ID: 6305060021 Enrollment ID: I20210622000613 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Janelle Santos |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1023549201 PECOS PAC ID: 4688075138 Enrollment ID: I20210622002278 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bukhari Burale |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1598255317 PECOS PAC ID: 9436408598 Enrollment ID: I20210624002562 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Angel David Aponte |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1992202071 PECOS PAC ID: 6103227905 Enrollment ID: I20210630003776 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katherine Emilie Rhoades Smith |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1316440126 PECOS PAC ID: 7012267651 Enrollment ID: I20210708001450 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kimberly Rodgers |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477837326 PECOS PAC ID: 9638345648 Enrollment ID: I20210712003829 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Claire Anne Zabransky |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1780115303 PECOS PAC ID: 7517360191 Enrollment ID: I20210720001150 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carol Conceicao |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1033644885 PECOS PAC ID: 7911300496 Enrollment ID: I20210721001442 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Yeshwanter Radhakrishnan |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1437635216 PECOS PAC ID: 4688925209 Enrollment ID: I20210721002979 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrew S Alexander |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1548825524 PECOS PAC ID: 7911321443 Enrollment ID: I20210722000882 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Elizabeth Sherrill Bermudez |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1073000972 PECOS PAC ID: 7618227398 Enrollment ID: I20210722000969 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John Patrick Welby |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1831728195 PECOS PAC ID: 5991121725 Enrollment ID: I20210722002222 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eric Twohey |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1063041556 PECOS PAC ID: 9234556556 Enrollment ID: I20210722002350 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Wade H Nedderman |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1649807181 PECOS PAC ID: 4688005366 Enrollment ID: I20210723000819 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Clifford Michael Csizmar |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1346878840 PECOS PAC ID: 8022432491 Enrollment ID: I20210724000001 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Melanie Jayne White |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1609404037 PECOS PAC ID: 2466876883 Enrollment ID: I20210726001963 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nikita Rafie |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1063040087 PECOS PAC ID: 5597189902 Enrollment ID: I20210727001285 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ashley Maree Stantz |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1780212241 PECOS PAC ID: 2264856632 Enrollment ID: I20210727001470 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas Ward Fredrick |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1265060305 PECOS PAC ID: 6608291240 Enrollment ID: I20210727001969 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sara Jane Tyree |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1720617178 PECOS PAC ID: 9638593999 Enrollment ID: I20210728003445 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas Edward Trischman |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1275161259 PECOS PAC ID: 6608290176 Enrollment ID: I20210728003682 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jacob Goodwin |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1962031914 PECOS PAC ID: 2769806140 Enrollment ID: I20210802000015 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joseph Albert Gottwald |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1992332985 PECOS PAC ID: 2860816147 Enrollment ID: I20210804001356 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dennis K Kobiri |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1083240956 PECOS PAC ID: 0345664710 Enrollment ID: I20210804003101 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Marisia Rose Young |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1104496066 PECOS PAC ID: 7719381375 Enrollment ID: I20210804003750 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Timothy Cogswell Evans |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1669000568 PECOS PAC ID: 6800210345 Enrollment ID: I20210805000017 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew Brian Amdahl |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1245868819 PECOS PAC ID: 3577986439 Enrollment ID: I20210805002072 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ikram-ul Haq |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1568074920 PECOS PAC ID: 1759708126 Enrollment ID: I20210809000041 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrea Leigh Hlady |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1831728997 PECOS PAC ID: 4183048556 Enrollment ID: I20210809000784 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Richard Ogunti |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1992236046 PECOS PAC ID: 8820374663 Enrollment ID: I20210811000019 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jacob Tyler Shreve |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1497242713 PECOS PAC ID: 4587917976 Enrollment ID: I20210812003059 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brittni Ashton Scruggs |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1942689252 PECOS PAC ID: 5597078071 Enrollment ID: I20210818002264 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gabriel Andres Martinez Alvarez |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1750849402 PECOS PAC ID: 7517388762 Enrollment ID: I20210819001748 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Samuel Michel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1831686781 PECOS PAC ID: 7517298318 Enrollment ID: I20210824001055 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paige Leann Dinse |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467125245 PECOS PAC ID: 3476958711 Enrollment ID: I20210824002998 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Erin M Rainosek |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1417576026 PECOS PAC ID: 5597189969 Enrollment ID: I20210826001294 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sean Huls |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1831718287 PECOS PAC ID: 3779988894 Enrollment ID: I20210826002797 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carmen Rae Holmes |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1114553013 PECOS PAC ID: 2769809904 Enrollment ID: I20210827002053 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Friederike D Froke |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1215403480 PECOS PAC ID: 1153741988 Enrollment ID: I20210830001231 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kaylie Pierce Dean |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1376171678 PECOS PAC ID: 2769806967 Enrollment ID: I20210831000517 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alex Chan |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1942620968 PECOS PAC ID: 4082834254 Enrollment ID: I20210831003219 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Caroline Louise Matchett |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1821626839 PECOS PAC ID: 2163846387 Enrollment ID: I20210902000221 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Phillip John Link |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1770111858 PECOS PAC ID: 8820411796 Enrollment ID: I20210902001183 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nasro Abdinur Isaq |
|---|---|
| Provider Type | Practitioner - Dermatology |
| Provider Identifiers | NPI Number: 1033748884 PECOS PAC ID: 8224453246 Enrollment ID: I20210902001893 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kenneth Robert Seid |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1154959575 PECOS PAC ID: 1355765553 Enrollment ID: I20210902002443 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bradley Thomas Busebee |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1215565809 PECOS PAC ID: 6103240577 Enrollment ID: I20210903001424 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dontre' M Douse |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1396372694 PECOS PAC ID: 4880018274 Enrollment ID: I20210904000008 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Cole R Marschke |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1265775191 PECOS PAC ID: 4688978802 Enrollment ID: I20210908001657 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jolene K Helgeson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235702192 PECOS PAC ID: 1557768546 Enrollment ID: I20210917000587 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kambiz Kalantari |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1619019189 PECOS PAC ID: 4183638927 Enrollment ID: I20210921001242 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Heidi Lee Schaffer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861169971 PECOS PAC ID: 1254738065 Enrollment ID: I20210921003514 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Leah Ursula Mccoy |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1588111058 PECOS PAC ID: 6406253889 Enrollment ID: I20210928001439 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah Ashley Lawrence |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1730708256 PECOS PAC ID: 2163847047 Enrollment ID: I20210929003154 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rami Sadek Awad Abdel Aziz |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1497252365 PECOS PAC ID: 8022355957 Enrollment ID: I20210930002642 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jillian Williamson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720752249 PECOS PAC ID: 7012315187 Enrollment ID: I20211005001444 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thomas Giju Lim |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1073141396 PECOS PAC ID: 8628492832 Enrollment ID: I20211005002687 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Carrie Ann Balster |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477222800 PECOS PAC ID: 1658779566 Enrollment ID: I20211007000571 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy Martin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598435570 PECOS PAC ID: 2860890167 Enrollment ID: I20211015002384 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Donnell Philippe Octavio Lazaro-paulina |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1922627462 PECOS PAC ID: 5890111074 Enrollment ID: I20211020001066 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Chelsea Powell |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1811524036 PECOS PAC ID: 9032533880 Enrollment ID: I20211203000274 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy J Weber |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265001242 PECOS PAC ID: 4587054358 Enrollment ID: I20211209002149 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christina N Andrist |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1801154059 PECOS PAC ID: 1951615657 Enrollment ID: I20211230001793 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hilary Bingol |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1730299983 PECOS PAC ID: 6507839792 Enrollment ID: I20220103000521 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rhonda Heun |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1306840988 PECOS PAC ID: 4082893706 Enrollment ID: I20220103000782 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dominika Jegen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1023528155 PECOS PAC ID: 1355617945 Enrollment ID: I20220105000121 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ahmad A Al-anii |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1609368224 PECOS PAC ID: 1951652726 Enrollment ID: I20220112001586 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paula Gill |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1750363909 PECOS PAC ID: 1557392883 Enrollment ID: I20220202002198 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David W Byrd |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1538658497 PECOS PAC ID: 3678828159 Enrollment ID: I20220204001694 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Anika Lin Kinniry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518626241 PECOS PAC ID: 1557755287 Enrollment ID: I20220223001574 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ashley J Bjornson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780335562 PECOS PAC ID: 0840684262 Enrollment ID: I20220301002302 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dana Mccray |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1437375870 PECOS PAC ID: 9234454562 Enrollment ID: I20220302002202 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael P Hafertepe |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1407388952 PECOS PAC ID: 0840541793 Enrollment ID: I20220302003015 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Laura Rae Shirley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639769284 PECOS PAC ID: 1456746437 Enrollment ID: I20220310001529 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Siaka Sanneh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073009981 PECOS PAC ID: 2769732825 Enrollment ID: I20220321002144 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Lorenza Saldivar |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912666579 PECOS PAC ID: 9931594348 Enrollment ID: I20220322002300 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kathryn K Vandreese |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1073993648 PECOS PAC ID: 6901114867 Enrollment ID: I20220323001959 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy Craker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598419210 PECOS PAC ID: 0749676039 Enrollment ID: I20220414000474 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Duy Nguyen |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1952442915 PECOS PAC ID: 6901930379 Enrollment ID: I20220420002432 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shaundra Riley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295157634 PECOS PAC ID: 0143453225 Enrollment ID: I20220422001345 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Elizabeth April Vanblaricom |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154079101 PECOS PAC ID: 6800283706 Enrollment ID: I20220423000055 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kirsten Education Lipps |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1235520966 PECOS PAC ID: 8527394931 Enrollment ID: I20220517002606 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ammar Alam |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1487175071 PECOS PAC ID: 2264831320 Enrollment ID: I20220517002773 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bayan Moustafa |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1720441967 PECOS PAC ID: 1153617352 Enrollment ID: I20220519000461 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Elizabeth Ender |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1376065813 PECOS PAC ID: 1456695006 Enrollment ID: I20220521000307 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alisha M Garel |
|---|---|
| Provider Type | Practitioner - Geriatric Medicine |
| Provider Identifiers | NPI Number: 1023660883 PECOS PAC ID: 1254718679 Enrollment ID: I20220524001158 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Prasanth Lingamaneni |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1265927149 PECOS PAC ID: 2567707706 Enrollment ID: I20220531000256 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daryl Glenn Sanford |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477293728 PECOS PAC ID: 7113305384 Enrollment ID: I20220531000416 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Corrine K Nelson |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1316436322 PECOS PAC ID: 3274887021 Enrollment ID: I20220609001663 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mohammad S Sheikh |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1518329960 PECOS PAC ID: 7113258708 Enrollment ID: I20220614003359 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Andrea Boni |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1760707624 PECOS PAC ID: 9931420007 Enrollment ID: I20220624001203 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Manik Aggarwal |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1659932796 PECOS PAC ID: 7113255530 Enrollment ID: I20220627001974 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joshua Brunton |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1750886198 PECOS PAC ID: 0840553012 Enrollment ID: I20220629002224 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Danielle N Westenberg |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1215427505 PECOS PAC ID: 3678821675 Enrollment ID: I20220701001068 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Paul Wesley Davis |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1437611019 PECOS PAC ID: 9739417783 Enrollment ID: I20220705000281 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew Steven Machacek |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1538809181 PECOS PAC ID: 9133509136 Enrollment ID: I20220708000558 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kelly Bruce |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1871024570 PECOS PAC ID: 9931458981 Enrollment ID: I20220712002392 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer Dens Higano |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1407435803 PECOS PAC ID: 6901209014 Enrollment ID: I20220714002299 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rochelle Lynn Pasche |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689338162 PECOS PAC ID: 0042691354 Enrollment ID: I20220718003430 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ahmed Salim |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1285286328 PECOS PAC ID: 7517348832 Enrollment ID: I20220719000183 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Girish Bathla |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1760737738 PECOS PAC ID: 2769621093 Enrollment ID: I20220720003101 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kirsten Pierce |
|---|---|
| Provider Type | Practitioner - Pathology |
| Provider Identifiers | NPI Number: 1871938142 PECOS PAC ID: 8527365600 Enrollment ID: I20220720003145 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Viola C Maritim |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518525880 PECOS PAC ID: 2860721032 Enrollment ID: I20220721000823 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sanghee Lim |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1730759556 PECOS PAC ID: 4284038324 Enrollment ID: I20220726000127 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Volha Ivanovna Mazziotto |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1922686757 PECOS PAC ID: 2668874397 Enrollment ID: I20220726001120 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Patrick Taylor Davis |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1306410642 PECOS PAC ID: 9638578487 Enrollment ID: I20220726001566 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Raquel T Cardenas |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1376045112 PECOS PAC ID: 5991187783 Enrollment ID: I20220726001704 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jacob Bradley Perera |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1568031268 PECOS PAC ID: 9830592690 Enrollment ID: I20220726001758 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kathryn Irene Breon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821727215 PECOS PAC ID: 7517349087 Enrollment ID: I20220729002422 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katherine Mia Choi |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1104320415 PECOS PAC ID: 5890177349 Enrollment ID: I20220801001932 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jawaad Hassan |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1053763243 PECOS PAC ID: 9931494812 Enrollment ID: I20220802002424 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dorissa Lahner Gursahaney |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1467815381 PECOS PAC ID: 3870870934 Enrollment ID: I20220802004056 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Micheal Rajni Thomas |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962089631 PECOS PAC ID: 4688075898 Enrollment ID: I20220803002261 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eliza Ruth Thompson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1871167593 PECOS PAC ID: 0648671875 Enrollment ID: I20220804000225 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David Samuel Franklin Kerner |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1447833702 PECOS PAC ID: 2860893088 Enrollment ID: I20220804001931 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mitchell Robert Cleghorn |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1730649427 PECOS PAC ID: 0244567204 Enrollment ID: I20220805000695 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Neelakanta Atkuri |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1902213424 PECOS PAC ID: 6406102961 Enrollment ID: I20220805002715 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicholas Reed Randall |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1093229452 PECOS PAC ID: 1850792078 Enrollment ID: I20220805002941 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kevin L Denton |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1518304930 PECOS PAC ID: 0840597829 Enrollment ID: I20220805003031 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Halden D Nielsen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1598343741 PECOS PAC ID: 4284035254 Enrollment ID: I20220805003040 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel Ritz Witt |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1710513510 PECOS PAC ID: 4385045509 Enrollment ID: I20220808001980 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hussen Amir Ahmed Mansai |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1790335446 PECOS PAC ID: 9234511189 Enrollment ID: I20220809002201 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Natasha Kaye Guillien |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467109256 PECOS PAC ID: 6002298973 Enrollment ID: I20220809002890 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jessica Daley White |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1891373270 PECOS PAC ID: 5890196083 Enrollment ID: I20220809003521 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rachel C Davis |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1508430919 PECOS PAC ID: 5092114843 Enrollment ID: I20220810000938 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Aditya Khurana |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1942836473 PECOS PAC ID: 0547643462 Enrollment ID: I20220810001001 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Karson Mostert |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1548847080 PECOS PAC ID: 2466854609 Enrollment ID: I20220812000739 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shada Ahrar |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1871156224 PECOS PAC ID: 8921335126 Enrollment ID: I20220812001764 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shire Jama |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1033773007 PECOS PAC ID: 3274916887 Enrollment ID: I20220815002407 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thuy-hong Le-kumar |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1598260101 PECOS PAC ID: 4688928971 Enrollment ID: I20220818003739 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jay J Pillai |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1972603439 PECOS PAC ID: 9234130493 Enrollment ID: I20220822001138 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sabina Kadariya |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1982343067 PECOS PAC ID: 5496138695 Enrollment ID: I20220822001495 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexander Lee Buchholz |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1588242671 PECOS PAC ID: 2567863848 Enrollment ID: I20220823000366 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daniel Sykora |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1992382709 PECOS PAC ID: 2668873886 Enrollment ID: I20220824000394 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sara Sutherland |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1730797366 PECOS PAC ID: 3577964550 Enrollment ID: I20220824002847 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ozan Dikilitas |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1871176883 PECOS PAC ID: 6305247669 Enrollment ID: I20220824003466 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Manfred Martin Kubler |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1871174193 PECOS PAC ID: 4587065792 Enrollment ID: I20220825000486 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brittanee Joyce Samuelson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1891323499 PECOS PAC ID: 2365843588 Enrollment ID: I20220825000557 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David Li Farrier |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1093397754 PECOS PAC ID: 0648671859 Enrollment ID: I20220825000798 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alexandria Rylander Roy |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1447828827 PECOS PAC ID: 1456752658 Enrollment ID: I20220825000840 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael Harrison Storandt |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1518545086 PECOS PAC ID: 4880095926 Enrollment ID: I20220825001296 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James Foster Howick |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043893373 PECOS PAC ID: 4880095009 Enrollment ID: I20220825001715 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Daria Hunter |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1871172197 PECOS PAC ID: 6800298027 Enrollment ID: I20220825002120 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Philip David Sang |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1467039263 PECOS PAC ID: 9436550654 Enrollment ID: I20220825003222 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Katie Ann Casper |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1750888947 PECOS PAC ID: 5395129118 Enrollment ID: I20220829000985 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mohamad El Labban |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1821608159 PECOS PAC ID: 4183040736 Enrollment ID: I20220829001583 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Taylor Laine Cammack |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1992383160 PECOS PAC ID: 1850792052 Enrollment ID: I20220830000713 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Badro Abdi Ali |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629656764 PECOS PAC ID: 6800297144 Enrollment ID: I20220830000846 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Yuan Provider Yao |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1306515895 PECOS PAC ID: 7012314693 Enrollment ID: I20220831000501 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nari Sohn |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1982263034 PECOS PAC ID: 6800270968 Enrollment ID: I20220908002941 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jeffrey David Okun |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1164823670 PECOS PAC ID: 0143605204 Enrollment ID: I20220910000365 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Cole Cheney |
|---|---|
| Provider Type | Practitioner - Pain Management |
| Provider Identifiers | NPI Number: 1922539568 PECOS PAC ID: 3779836267 Enrollment ID: I20220912000652 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher J Sigakis |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1629364310 PECOS PAC ID: 2466751979 Enrollment ID: I20220912002808 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rachel Marie Schroeder |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1063131688 PECOS PAC ID: 1052796919 Enrollment ID: I20220914001036 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shelby Elizabeth Olsen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487372108 PECOS PAC ID: 9133504095 Enrollment ID: I20220914001084 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Elizabeth Renae Kurtti |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053040360 PECOS PAC ID: 4183000276 Enrollment ID: I20220927001254 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matthew Paul Hamilton |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1346814951 PECOS PAC ID: 2668873712 Enrollment ID: I20220928000177 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adiba Matin |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1447825385 PECOS PAC ID: 9436550621 Enrollment ID: I20220928001297 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Heather Ann Miller |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689301921 PECOS PAC ID: 7315323623 Enrollment ID: I20221010001635 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gbemisola Tolulope Olorode |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629311220 PECOS PAC ID: 1658663877 Enrollment ID: I20221013001884 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kelsey L Western |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1255894416 PECOS PAC ID: 7113252230 Enrollment ID: I20221014000728 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Karissa Kay Buck |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134840101 PECOS PAC ID: 2062888936 Enrollment ID: I20221018000669 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Harish Aroor Kinni |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1023379179 PECOS PAC ID: 5193957967 Enrollment ID: I20221018001275 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicole L. Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861015893 PECOS PAC ID: 2860868783 Enrollment ID: I20221018002455 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kaneisha Monique Thompson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1972168870 PECOS PAC ID: 2062743008 Enrollment ID: I20221019000337 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ajay Singh Sekhon |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1306125109 PECOS PAC ID: 2264808013 Enrollment ID: I20221019000397 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Brian Hesler |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1699949370 PECOS PAC ID: 6709178932 Enrollment ID: I20221019002444 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Krzysztof Laudanski |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1760579643 PECOS PAC ID: 0143414938 Enrollment ID: I20221027000521 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tabita Amoatemaa Darkwah |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1164156535 PECOS PAC ID: 8628444395 Enrollment ID: I20221101001313 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Laura Jorgenson |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1962081307 PECOS PAC ID: 7810392230 Enrollment ID: I20221107000713 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Harnek Singh |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1811917917 PECOS PAC ID: 1951296961 Enrollment ID: I20221116000446 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Michael Shane Stephens |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1427638774 PECOS PAC ID: 8820499957 Enrollment ID: I20221118002229 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer Helen Clement |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1992268452 PECOS PAC ID: 0143698340 Enrollment ID: I20221118002287 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Ryan Michael Chavez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427643337 PECOS PAC ID: 6800284142 Enrollment ID: I20221121001447 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy M Monsour |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1326304700 PECOS PAC ID: 3870757826 Enrollment ID: I20221130002559 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alan Howard Stolpen |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1760470629 PECOS PAC ID: 2062554702 Enrollment ID: I20221206000869 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bradley L Houston |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1275529240 PECOS PAC ID: 4587612064 Enrollment ID: I20230105002027 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gagandeep Singh |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1083993687 PECOS PAC ID: 4284866021 Enrollment ID: I20230110002111 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alix Hopp |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1154770774 PECOS PAC ID: 8729356829 Enrollment ID: I20230124000053 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dean F Leslie |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1619926664 PECOS PAC ID: 6305857749 Enrollment ID: I20230203000396 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Adam Joseph Langer |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1477057529 PECOS PAC ID: 2062769664 Enrollment ID: I20230209001181 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah Joy Hummer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447965256 PECOS PAC ID: 8729450770 Enrollment ID: I20230221000922 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jenna Marie Nelson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942917265 PECOS PAC ID: 8628441474 Enrollment ID: I20230227002147 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Madeline Bonifacio |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1831815083 PECOS PAC ID: 8325411739 Enrollment ID: I20230306002759 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kylie Marie Cooper |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1043509730 PECOS PAC ID: 9133435688 Enrollment ID: I20230307002379 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Britt Kiersten Schultz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053019372 PECOS PAC ID: 1254704554 Enrollment ID: I20230308000645 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joanna Kusmirek |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1538336706 PECOS PAC ID: 7810205911 Enrollment ID: I20230308002937 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John Wood |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1891451365 PECOS PAC ID: 1254705460 Enrollment ID: I20230329001229 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jesse M Reiter |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1992202709 PECOS PAC ID: 5799034021 Enrollment ID: I20230331001324 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Cassandra M Miles-hanson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609580208 PECOS PAC ID: 5698140796 Enrollment ID: I20230403001352 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer Rose Bailey |
|---|---|
| Provider Type | Practitioner - Clinical Psychologist |
| Provider Identifiers | NPI Number: 1114448156 PECOS PAC ID: 6709251820 Enrollment ID: I20230403002241 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Amy Lynn Arcand |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194421925 PECOS PAC ID: 6709251507 Enrollment ID: I20230410001213 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David M Kushner |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1922009224 PECOS PAC ID: 7315931292 Enrollment ID: I20230411002286 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Christopher D Byers |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1891227252 PECOS PAC ID: 2961756051 Enrollment ID: I20230412000664 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | David F Slat |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1528223807 PECOS PAC ID: 9436297447 Enrollment ID: I20230424000112 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicholas L Bormann |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1750879367 PECOS PAC ID: 3870849490 Enrollment ID: I20230427000327 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gabriella Avitia |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497421366 PECOS PAC ID: 2769880624 Enrollment ID: I20230427000997 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Dominick A Siconolfi |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1255823415 PECOS PAC ID: 6709295314 Enrollment ID: I20230517002927 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Valerie Jaroenpuntaruk |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1033774104 PECOS PAC ID: 2769885193 Enrollment ID: I20230518002462 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Eugene Chiemeka Nwankwo |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1285253328 PECOS PAC ID: 3072938547 Enrollment ID: I20230525000108 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stephen Ferguson |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1487281911 PECOS PAC ID: 8628490703 Enrollment ID: I20230530001354 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Melanie Marie Haak |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1629737317 PECOS PAC ID: 3779940119 Enrollment ID: I20230531000559 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Graciela Maldonado |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1831650852 PECOS PAC ID: 2466787650 Enrollment ID: I20230607000567 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Cameron M Koch |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1134658743 PECOS PAC ID: 3971872003 Enrollment ID: I20230622003335 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Aswin Kumar |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1629469382 PECOS PAC ID: 5799184628 Enrollment ID: I20230703000514 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rachel P Ferguson |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1205463734 PECOS PAC ID: 9638591589 Enrollment ID: I20230711001556 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Annie M Kontos |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1255331401 PECOS PAC ID: 6305838004 Enrollment ID: I20230714000794 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sujatha Narayanamoorthy |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1124673538 PECOS PAC ID: 9739418328 Enrollment ID: I20230719002760 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicole Christine Sztuk |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1932631504 PECOS PAC ID: 7618240144 Enrollment ID: I20230725003096 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mackenzie Dale Maberry |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1871233718 PECOS PAC ID: 5092195495 Enrollment ID: I20230727003749 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Alind Zeki Amedi |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1235888520 PECOS PAC ID: 7012395528 Enrollment ID: I20230728001143 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Madison Lea Horstman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962187393 PECOS PAC ID: 6901267350 Enrollment ID: I20230801002471 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Matteo Castrichini |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1477207181 PECOS PAC ID: 0749660488 Enrollment ID: I20230804000142 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Samuel Nowicki |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1982278198 PECOS PAC ID: 4082076724 Enrollment ID: I20230814000778 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Priscilla Koirala |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1770226862 PECOS PAC ID: 4082094701 Enrollment ID: I20230814002241 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Shelby Augusta Swartz |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1770229841 PECOS PAC ID: 0749642338 Enrollment ID: I20230814003004 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Hayden Jon Swartz |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1396481727 PECOS PAC ID: 8628430220 Enrollment ID: I20230814003742 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Robert Joseph Haemmerle |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1104568146 PECOS PAC ID: 5294115010 Enrollment ID: I20230815002397 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Crina L. Manole Weddle |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1215552096 PECOS PAC ID: 4880013010 Enrollment ID: I20230824002014 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Bradley Nitzsche |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1790190890 PECOS PAC ID: 9032430004 Enrollment ID: I20230831003468 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | James C Nesler |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1255342119 PECOS PAC ID: 9133123912 Enrollment ID: I20230915001023 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kathryn Johnson |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1760163802 PECOS PAC ID: 7719341239 Enrollment ID: I20230915001519 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Gayathri Chalikonda |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1346877982 PECOS PAC ID: 9830509447 Enrollment ID: I20230918000162 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Rebecca Heart Chun |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1316697709 PECOS PAC ID: 4981068350 Enrollment ID: I20230919000899 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Devin M Shaheen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174307169 PECOS PAC ID: 0446614747 Enrollment ID: I20230919002321 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | John Earl Yeakel |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1467959353 PECOS PAC ID: 9931456977 Enrollment ID: I20230921000321 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Richard W Stephens |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1700413655 PECOS PAC ID: 0648699876 Enrollment ID: I20231002000523 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Joyce D Schroeder |
|---|---|
| Provider Type | Practitioner - Interventional Radiology |
| Provider Identifiers | NPI Number: 1295834067 PECOS PAC ID: 0749287217 Enrollment ID: I20231003003268 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Pamela I Causa Andrieu |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1437702727 PECOS PAC ID: 9335551738 Enrollment ID: I20231005001200 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Krina Bhimjibhai Viroliya |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1396373676 PECOS PAC ID: 8224469515 Enrollment ID: I20231009000116 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sabarish Narayanasamy |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1376039669 PECOS PAC ID: 6103173851 Enrollment ID: I20231018001430 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kelly Sue Goszkowicz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346906823 PECOS PAC ID: 7113372657 Enrollment ID: I20231018001817 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Thanh Cong Hoang |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1861061673 PECOS PAC ID: 9234509464 Enrollment ID: I20231026002407 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Stuart Alan Ostby |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1043743487 PECOS PAC ID: 6204112428 Enrollment ID: I20231110002256 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Nicole S Petersen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255055950 PECOS PAC ID: 6103296868 Enrollment ID: I20231205002462 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Kholoud Abdulaziz A Arab |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1841921384 PECOS PAC ID: 3375994254 Enrollment ID: I20240104002128 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Tonya L Wolter |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1548950884 PECOS PAC ID: 2365893674 Enrollment ID: I20240111001979 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Douglas M Panser |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1821165309 PECOS PAC ID: 7517318744 Enrollment ID: I20240111002945 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Olaf Js Samuelson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1013535988 PECOS PAC ID: 4981056512 Enrollment ID: I20240119001217 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Mariah Marie Diercks |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1659971554 PECOS PAC ID: 2961855481 Enrollment ID: I20240131001675 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Jennifer J Johnson Krotzer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992571970 PECOS PAC ID: 4688027915 Enrollment ID: I20240202000047 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
| Provider Name | Sarah Mary Stinson |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1316912645 PECOS PAC ID: 0042655458 Enrollment ID: I20240226001122 |
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
News Archive
OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.
California health regulators have allowed poor care to proliferate at nursing homes around the state, and the number of incidents that could cause serious injury or death has increased significantly in recent years, according to a stinging state audit released this week.
Genetic processes that allow cells to transform so they can mend damaged nerves have been identified by scientists.
A cutting-edge test developed in South Australia has the potential to expedite the worldwide quest to develop better treatments, or even a cure, for the Motor Neuron Disease (MND).
› Verified 3 days ago
Patient's Choice Wellness Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 904 1/2 E Plaza St, Albert Lea, MN 56007 Phone: 507-821-1051 | |
Touchworks Chiropractic, P.a. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1629 W Main St, Albert Lea, MN 56007 Phone: 507-373-1940 | |
Mercyone Albert Lea Family Medicine & Specialty Care Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2440 Bridge Ave, Albert Lea, MN 56007 Phone: 507-473-2249 Fax: 507-473-2088 |